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SUMMARY
Factor VIII inhibitors (antibodies) can arise in patients with inherited haemophilia A as an
immune response to infused factor VIII, or can cause acquired haemophilia A in
individuals with a previously normal factor VIII level. Two different types of factor VIII
inhibitors form, with different kinetics. Type I inhibitors inactivate all factor VIII
available, and usually develop in inherited haemophilia A. Type II inhibitors have more
complex kinetics; not all factor VIII is neutralised, and they are usually seen in acquired
haemophilia. Fields of interest for the study of these inhibitors include the mechanisms
of inactivation of factor VIII coagulant activity (FVIII:C) and determination of their
binding sites (epitopes). Research concerning such scientific interests may also have
practical application purposes in the future, in terms of improving the therapeutic
strategies of haemophilia patients with inhibitors.
The f,rrst part of my project focused on the in vitro kinetics of factor VIII inhibitors,
aiming to re-examine the available methodology for characterising the kinetics of
inhibitor binding to factor VIII, and to evaluate their practicality and sensitivity
Antibody concentration studies, time course studies and alternative approaches were
assessed, using modifications of the Bethesda assay to measure the effect of inhibition.
Statistical analyses were performed, including mathematical modelling of kinetic data.
My work highlighted difhculties in comprehension, execution and interpretation of
results using previously described methods. During the course of the project a simple and
practical approach to classiff inhibitors was developed. The main conclusion was that
the use of plasma dilution studies was a readily standardised method to distinguish type I
inhibitors from type IL Other strategies to classiff inhibitors were less successful. In
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cases with a low-titre inhibitor (<10 BU/ml), purified and concentrated IgG was
necessary to enable classification. In our study group of 11 patients (5 severe, 3 mild and
3 acquired), eight type I and three type II inhibitors were found using a combination of
both observation and mathematical methods. This is the first time that a systematic study
of methods to evaluate in vitro kinetics of factor VIII inhibitors has been performed to
classiff inhibitor types in a small but diverse group of patients with haemophilia A.
The second aim of the project was to establish and evaluate ELISA methodology to detect
factor VIII antibodies. This method has the ability to detect antibodies which do not
inhibit the function of FVIII:C, as well as those that do. Using the ELISA method, some
workers showed a very high prevalence of antibodies in patients with severe inherited
haemophilia A with the intron 22 inversion of the factor VIII gene. Therefore, specific
attention was paid to comparing the ELISA method with the conventional Bethesda
assay, and to determining whether there was any difference in the prevalence of
antibodies in severe patients with and without the intron 22 inversion. Samples with a
wide range of inhibitor titres by Bethesda assay were studied, as well as samples from a
group of haemophilia patients with no detectable inhibitor. Formulated recombinant
factor VIII was used to coat the micro-titre plates, and a range of plasma dilutions from
both normal individuals and patients was tested. The conclusion was that in our study
group of 50 haemophilia A patients, the ELISA method revealed a level of sensitivity for
detection of factor VIII antibodies that was similar to the Bethesda assay. In addition,
ELISA showed that the prevalence of antibodies in severe patients with intron 22 gene
inversion was similar to that in those without the inversion. An ELISA method using
unformulated recombinant factor VIII has also been established, and this will be used to
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screen a number of patients to give more information about this method and its sensitivity
for detecting factor VIII antibodies
The third aim of the project was to investigate methods for epitope mapping of the factor
VIII molecule. Thrombin-cleaved recombinant factor VIII was studied by Western
blotting to detect fragments which bind to monoclonal antibodies. The heavy chain and
its activatiorVinactivation products from thrombin cleavage were demonstrated to bind to
monoclonal anti-heavy chain antibody MAS 530. Experimental conditions to detect
binding of patient antibodies need to be optimised. A bacterial expression system to
produce A1 fragment was attempted but was not successful. Evidence was obtained to
show that the vector gene (with the A1 gene) was inserted into E. Coli cells. However it
was not possible to express the protein (Al fragment) using this system. Although the
methodology remains a challenge, using recombinant DNA technology to produce
fragments of factor VIII of any desired size and section of the molecule still seems to be a
reasonable way to carry out a thorough study of epitope determination.
The work done for this project has initiated the study of a possible relationship between
the epitope specificity, genetic defect, and clinical and kinetic features of factor VIII
inhibitors. Future studies may give additional information about the mechanisms of
antibody formation and their inactivation of FVIII:C, which may lead not only to more
informed and effective therapeutic approaches for haemophilia patients with inhibitors,
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In this review of the literature on factor VIII inhibitors in haemophilia A, specific attention
has been paid to the three selected features, namely, the in vitro kinetics of factor VIII




The word haemophilia is defined by The Oxford English Dictionary as "a constitutional
(usually hereditary) tendency to bleeding, either spontaneously or from very slight injuries;
haemorrhagic diathesis" (Simpson and Weiner, 1989). This disease was known to the
ancient world, with the earliest written references in Jewish texts of the second century AD
(Ingram, 1997). The first modern description of haemophilia is attributed to Dr' John
Conrad Otto, who clearly appreciated, in his publication in 1803, the three cardinal
features of haemophilia: an "inherited" tendency of "males" to "bleed" (Ingram, 1997).
However, the biochemical basis of haemophilia was not elucidated until the early 1950's,
when it was demonstrated that some proteins from normal plasma would correct the
abnormal clotting of haemophilic blood (Aggeler et al.,1952; Pavlovsky, 1947). Most of
the patients with haemophilia were found to be missing the protein known as
antihaemophilic factor (AHF), and the disease was termed haemophilia A. Some patients
with identical clinical and genetic features were found to be lacking a different protein,
Christmas factor, and their disorder was termed haemophilia B. Standardised names were
assigned to the various coagulation factors by the International Committee on Thrombosis
and Haemostasis in 1962: the factor missing in haemophilia A was subsequently termed
factor VIII, and the factor missing in haemophilia B was termed factor IX (Wright,1962).
Haemophilia A is the most common form and accounts for about 80% of the two main
forms of the haemophilias associated with a coagulation factor deficiency or defect. Thus
the unqualified term haemophilla is classically understood to refer to haemophilia A
(Brettler and Levine ,1993). Haemophilia A is described as an inherited blood coagulation
disorder caused by the absence or insufficient amount of functional factor VIII, a plasma
protein which is essential for blood to clot (Brettler and Levine, 1993; Handin, 1998 a;
Mosher, 1996). This recessive, X-linked genetic disease affects approximately one out of
10,000 males in the population, and is found to exist in all races with a similar incidence in
all areas of the world (Brettler and Levine,1993; Hoyer 1994; Levine, 1987). It is known
lhat a great variety of factor VIII gene mutations, located on the X chromosome, are
responsible for the aetiology of the lack or deficient activity of clotting factor VIII (Hoyer,
1981; Lozi..j:. and High, 1990; Hoyer, 1994; Tuddenham et al',1994)'
1.2 Clinical Presentation
The bleeding symptoms with haemophilia A usually occur during childhood and then
continue into adult life. The clinical manifestation in severe cases is characterised by
spontaneous and recurrent bleeding into soft tissues, muscles, and weight-bearing joints,
notably the knees, ankles, elbows and shoulders. The repeated presence of blood in joints
will subsequently lead to haemarthrosis and then severe joint deformity, which is known as
disabling haemophilic arthropathy. This, together with internal bleeding such as
oropharyngeal and central nerve system bleeding, accounts for the apparently reduced life
2
expectancy for haemophilia A patients before effective replacement therapy was
introduced at the end of the 1960's (Aledort, 1976; Biggs, 1.977; Eyster et a|.,1978)' The
laboratory investigations usually reveal a prolonged activated partíal thromboplastin time
(ApTT), with other tests such as platelet count, bleeding time (BT) and prothrombin time
(pT) being normal. Specific bioassays to quantitate factor levels are essential to
distinguish haemophilia A from haemophilia B (Handin, 1998 a; Mosher' 1996)'
Normal haemostasis requires a minimal level of 25-30% of factor VIII coagulant activity
(FVIII:C) in plasma, with a normal range of FVIII:C found to be around 50%-200% (0.50-
2.00 International Units (IU)/ml plasma) (Brettler and Levine, 1993; Handin, 1998 a).
However, symptoms usually occur when the FVIII:C levels ate 5Yo ot less, with a close
relation between the clinical severity of haemophilia and plasma FVIII:C level- There are
three clinical phenotypes of this disease observed and classified: severe haemophilia with
less than 1% of FVIII:C (<0.01 IU/ml) and frequent episodes of spontaneous haemorrhage;
moderate haemophilia with the plasma FVIII:C between 1-5% (0.01-0.05 IU/ml) and
haemorrhage provoked by slight trauma; and mild haemophilia with the FVIII:C over 5o/o
(>0.05 IU/ml) and infrequent bleeding that is usually secondary to major trauma (Brettler
and Levine , !993;Furie e/ a1.,1994; Handin, 1998 a; Mosher, 1996)'
1.3 Treøtment
1.3. 1 Replacement theraPY
A remarkable evolution in haemophilia A replacement therapy has occurred over the past
few decades. More than 30 years ago, the treatment for bleeding episodes was by the
infusion of whole blood and later frozen plasma, both of which were severely limited
J
therapies. With the discovery of concentrated factor VIII in plasma cryoprecipitate by
pool and coworkers in 1964 (Pool et al., 1964), more specific and effective therapy
became available. The subsequent continuous development of many novel manufacturing
methods for purified factor VIII concentrate has further revolutionised treatment (Aledort,
1996;Hoyer, 1994;Ingram, 1997 Rosendaal et al-,1991).
It has been empirically determined that each unit of factor VIII infused, which is defined as
the average amount present in 1 ml normal plasma, will elevate the recipient's factor VIII
level in plasma by 0.02 unit per kilogram of body weight. A 70-kg patient with severe
haemophilia A requires approximately 3000 units of factor VIII to raise the plasma level to
the average of that found in normal subjects (100% or 1 IU/ml). As a rule of thumb,
infusions of 15, 30 and 60 units per kilogram should raise the plasma level to 25o/o, 50yo
and l00o/o of normal, respectively (Mosher,1996). Factor VIII distributes mainly in the
blood plasma and the half-life is 10-12 hours (Mosher, 1996).
The amount of factor VIII required depends on the plasma level of factor VIII needed to
treat the specific bleeding episode. The distribution and clearance of the factor in plasma
should also be taken into consideration (Brettler and Levine, 1993; Handin, 1998 a; Hoyer,
1994; Mosher, 1996). In general, an uncomplicated episode of soft tissue bleeding or an
early haemarthrosis can be treated with one infusion of suff,rcient factor VIII concentrate to
raise the factor VIII level to l5o/o or 20o/o of normal. A more extensive haemarthrosis or
retroperitoneal bleeding requires twice or three times-daily or continuous infusions in
order to keep the factor VIII level above 25o/o for at least 72 hours. Life-threatening
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bleeding or major surgery may require therapy for 2 weeks with levels kept at a mlnlmum
of 50Yo of normal (Handin, 1998 a)
With the introduction of prophylactic therapy for haemophilia children from an early age
to prevent joint bleeds, and with the availability of home treatment or self-management
with factor VIII concentrate injections, the lifestyle for haemophilia A patients has
improved significantly in the last decade, with an anticipation of using standard gene
therapy treatment to cure the disease in the future (Berntorp et al.,1995; Furie, 1994).
1.3.2 Complications
However, with the benefits of replacement therapy of factor VIII, there are also some
complications, including viral transmission such as hepatitis B, hepatitis C, and human
immunodef,rciency virus, and the development of anti-factor VIII antibodies (factor VIII
inhibitors) as an immune response to infused factor VIII. The adoption of different
virucidal methods during the manufacturing process of plasma-derived factor VIII and
genetically-engineered products have offered a better margin of biological safety against
viral transmission than in the past (Berntorp et aL.,1995; Gilles et al., 1997; Lusher, 1987).
Following multiple transfusions, about 10-20% of severe haemophilia patients develop
inhibitors to factor VIII which neutralise FVIII:C, making the usual doses of replacement
therapy ineffective. Patients with inhibitors are usually divided into two basic categories
low responders, whose inhibitor titre usually does not exceed 10 Bethesda units/ml
(BU/ml) despite repeated exposure to factor VIII; and high responders, who have an
5
anamnestic response to repeated administration of factor VIII, and in whom the inhibitor
titre rises above 10 BU/ml (Roberts and Hoffman, 1995)'
In acute situations, patients with inhibitors can sometimes be treated effectively with very
high doses of human factor VIII or with porcine factor VIII. As a long-term solution, it is
sometimes possible to induce immune tolerance. However, the treatment for such patients
is usually problematic and extremely expensive. Therefore, the presence of factor VIII
inhibitors is now considered to be a major difficulty in the clinical management of
haemophilia A (Berntorp et al.,1995; Gilles et a\.,1997; Lusher, 1987).
1.4 Acquired HaemoPhilia A
Autoantibodies directed against factor VIII may also occur spontaneously in individuals
with a previously normal FVIII:C level, causing acquired haemophilia A. The incidence
of acquired haemophilia A is thought to be approximately 0.2 to 1.0 per million
population, with equal sex prevalence (Green and Lechner, 1981; Shapiro and Hultin,
1975; Shulman and Hirschman, 1969). It may be associated with particular medical
conditions, such as pregnancy and the postpartum period, autoimmune disorders,
malignancy, and drug allergic reactions, or may be idiopathic, without any identif,red
underlying conditions (Feinstein, 1993; Mosher, 1996; Sallah, 1997). The precise
aetiology of inhibitors to factor VIII in these non-haemophilic persons remains obscure.
The spectrum of symptoms in patients with acquired haemophilia A is similar but not
identical to that observed in congenital haemophilia. Haemarthrosis, for example, is
uncommon in acquired haemophilia, whereas it is the hallmark of congenital (severe)
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haemophilia (Mannucci and Giangrande, 1994). The acquired inhibitors share several
features with the factor VIII antibodies seen in hereditary haemophilia, e.g., both are
primarily of the immunoglobulin class G (IgG), and are usually directed against limited
epitopes in the factor VIII molecule, destroying coagulant activity. However, there are
many differences between these two kinds of inhibitors, including the degree of antibody
heterogeneity, reaction kinetics between inhibitor and factor VIII, patient demographics,
type and severity of bleeding, natural history, and therapeutic considerations (Lusher,
1e9s).
2. Factor VIII
2. 1 Coaguløtion PathwøY
Haemostasis is an extremely important biological mechanism that provides a rapid, potent,
but tightly localised response to vascular damage. It is comprised of two stages: primary
haemostasis and secondary haemostasis. Primary haemostasis includes the processes of
blood vessel contraction, platelet adhesion and aggregation immediately after tissue injury.
Secondary haemostasis is the process of blood coagulation. It is initiated by substances in
injured tissues and propagated by an interlocking network of zymogen-to-proteinase
conversions. Blood coagulation results in the formation of a stable fibrin clot that stops
further bleeding, thereby allowing subsequent cellular ingrowth and tissue repair to take
place (Furie and Furie, 1995; Jesty and Nemerson, 1995; Mosher, 1996).
For in vitro analysis by the clotting tests PT and APTT, the coagulation cascade was
divided into two branches: the intrinsic and extrinsic pathway, based on the mechanism by
which factor X is activated. Regardless of which pathway initiates the enzyme-catalysed
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reactions, the two will converge to a common pathway leading to generation of thrombin
(activated factor II, or IIa), the master coagulation eîzyme (Loziî.,. and High, 1990;
Mosher, 1996).
2.1.1 New concepts øhout the coagulation pathwøy
Recent research shows that the coagulation cascade is a complex interaction between
enzymes, and that the primary initiating event in vivo is exposure of tissue factor (TF), and
its formation into a complex with activated factor vII (vIIa) (Mann, 1999)' TF, the
activating substance which is usually found in the tissues rather than in the blood, is a
transmembrane glycoprotein expressed on most nonvascular cells and is inducible via de
novo synthesis in cells within the blood or on the blood vessel wall, including monocytes
and endothelial cells (Furie and Furie, 1995). Upon the formation of the tissue factor-
activated factor VII complex (TF:FVIIa) following tissue injury and laceration of blood
vessels, the initial product of the complex is factor Xa. Once Xa is generated, it
contributes to factor IX activation by a concerted reaction with TF:VIIa. Thus both the
intrinsic and extrinsic pathways are initiated (Mann, 1999). According to the new concept
about the biochemistry and physiology of blood coagulation, because there are several
recognised interactions between the two pathways, it is no longer accurate to view them as
separate pathways. However, these two pathways are still measured separately in the in
vitro hests. (Figure 1.1)
2.1.2 Contøct øctivatíon pathway (formerly known as intrinsic pathway)
ApTT measures the pathway previously known as the intrinsic pathway. In this assay,
activation of the pathway occurs when certain coagulation proteins come into contact with
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FIGURE 1.1 A Schematic Diagram of Some of the Clinically Important
Coagulation Reactions
The inactivated or precursor proteins are indicated by roman numbers, and the active form
by the addition of a lowercase "a" (a standard convention). Other abbreviations: Ca,
calcium; PL, phospholipid; TF: tissue factor. Arrows: those in blue stand for the activation
of precursor proteins to their active form; those in red stand for the activation or positive
feedback by one factor to another; those in back stand for the inhibition or negative
feedback. There are two independent activation pathways, the contact activation pathway
(formerly known as intrinsic pathway) and the tissue factor pathway (formerly known as
extrinsic pathway). They merge at the point of factor X activation and lead to the
generation of thrombin, which converts fibrinogen into fibrin (not shown on this diagram).
In addition, TF-VIIa can activate factor IX which is in the contact activation pathway.
These reactions are regulated by a number of negative feedbacks, namely, the inactivation
of factor V, VIII, and IX by thrombin, and the inactivation of TF-VII by Xa. Also, the















a negatively charged surface (Jesty and Nemerson, 1995; Mosher, 1996). These
coagulation proteins are found within the blood (hence the term intrinsic) and are known as
contact activation factors. They include prekallikrein (PK), high-molecular-weight
kininogen (HMWK), factor XII and factor XI (Mosher,1996)'
Upon contact with a negatively charged surface, the contact activation factors interact. The
presence of HMWK, during this interaction, causes the conversion of PK into kallikrein.
This, in turn, activates factor XII to form XIIa (the activated state). In the presence of
calcium (Ca), XIIa activates HMWK-bound factor XI into XIa (the activated state), which
then activates factor IX (Lozier and High, 1990). After this series of reactions, activated
factor IX (IXa) combines with activated cofactor VIII (VIIIa) and platelet factor 3 (PF3, a
phospholipid supplied by platelets), and in the presence of calcium, it converts factor X of
the common pathway to the serine protease Xa (the activated state). This is followed by
subsequent reactions: the activation of factor II to thrombin (IIa) by Xa, then the cleavage
of fibrinogen to fibrin by thrombin, and the formation of a blood clot (Jesty and Nemerson,
L995;Lozier and High, 1990; Mosher, 1996). The APTT test is used to assess the factors
in the intrinsic and common pathways (Mosher, 1996)'
2.1.3 Tßsuefactor pathway (formerly known as extrinsic pathway)
pT measures the pathway previously known as the extrinsic pathway. In this assay'
activation occgrs following exposure of tissue factor to plasma factor VII and the formation
of a TF:VII complex. From this interaction, factor VII is activated to the serine protease
VIIa, producing the TF:VIIa complex. This complex, in the presence of calcium and
phospholipid (PL), activates factor X to Xa, causing the subsequent reactions in the
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common pathway. PT measures the factors of the extrinsic and common pathways
(Handin, 1998 b; Mosher, 1996)
2.1.4 Regulation of the coaguløtíon pathway
For maximum effectiveness, the coagulation pathway is regulated by both positive and
negative feedbacks by activated factors such as Xa and IIa, or circulating plasma inhibitors
such as Antithrombin III, protein S and protein C, to either accelerate or localise the
coagulant reactions (Jesty and Nemerson, 1995). There is also a unique type of negative
control via a recently discovered protein, the so-called tissue factor pathway inhibitor
(TFpI). It is now thought that factor IX and X activation by the TF:FVIIa complex plays a
major role in the initiation of haemostasis. Once coagulation is initiated by this interaction,
TFpI combines with factor Xa, then inhibits the TF:VIIa complex and therefore blocks that
pathway. So elements of the intrinsic pathway, particularly factor VIII and IX, become the
dominant regulators of thrombin generation (Handin, 1998 b; Jesty and Nemerson, 1995).
2.2 Rote of Factor VIII in Blood Coagalation
In the blood coagulation cascade, the role of glycoprotein cofactors (factor V and factor
VIII) is essential. After being activated by thrombin, factor VIIIa accelerates the rate of
cleavage of factor X by IXa, causing a 56-fold enhancement of factor IXa activity under
physiological conditions (Lozier and High, 1990). A very low concentration of factor VIII
(0.2 ¡:,glml in plasma) ensures adequate procoagulant function in normal persons; a
substantial reduction (to less than 20Yo of normal) or absence of factor VIII leads to a
bleeding disorder (HoYer, 1994)'
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Factor VIII circulates in the plasma in a noncovalent complex with von Willebrand factor
(vV/F), a property that protects it from proteolysis, and concentrates it at sites of active
haemostasis (Hoyer, 1981; Kaufman et a1.,1989; Weiss et a1.,1977). The interaction with
vWF inhibits FVIII:C. To participate in haemostasis the factor VIII must separate from
vWF. This requires the cleavage of factor VIII by thrombin or factor Xa, which enables
factor VIII to bind to the phospholipid surfaces of damaged cells and adherent activated
platelets, where it dramatically increases the maximal velocity of the enzyme-substrate
reaction of factor IXa with factor X, accelerating it several thousandfold (Hoyer, 1981).










The factor VIII protein can be identified in two ways, by functional and immunological
methods. Factor VIII procoagulant activity (FVIII:C) refers to its functional property in
blood coagulation, while factor VIII procoagulant antigen (FVIII:Ag) refers to its antigenic
character measured by immunoassays (Hoyer, 1981; Mann et a|.,1990:. van Dieijen et al.,
1 e8 1).
2.3 Humøn Føctor VIII Molecule
Human factor VIII is a 235l-amino-acid polypeptide from which a hydrophobic signal
peptide of 19 amino acids is removed during secretion. Following the signal peptide is the
factor VIII protein with the triplicated amino acid domains, Al, A2 and A3 which have
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approximately 40 percent sequence homology with each other. A large B domain
separates the A2 and A3 domains, and at the carboxyl terminus are two duplicated C
domains (Hoyer, 1994;Lozier and High, 1990). Electron microscopy of rotary-shadowed
human factor VIII suggests a configuration of a globular structure 14 nm in diameter and a
B-domain tail that is released by thrombin cleavage (Fowler et al',1990).
The structural domains of factor VIII occur in the order NH2-Al(amino acid residues 1-
372)-A2(373-740)-B(74r-168e)-A3(t6e0-2019)-C1(2020-2172)-C2(2t73-2332)-COOH.
It is generally accepted that both A2 and C2 are important functional domains, as the A2
domain is involved in factor IXa binding, while the A3 and C2 domains are involved not
only in factor IXa binding, but also v'WT binding and phospholipid binding (Kaufman and
Antonarakis, 1995). (Figure 1'2)
Shortly after synthesis, factor VIII is cleaved during intracellular processing so that plasma
factor VIII is a heterodimer: an 8O-kilo Dalton (KD) light chain in a divalent, cation-
dependent complex with a heavy chain that contains one B domain of variable length. On
exposure to thrombin or factor Xa, cleavage at Arg372 converts the heavy chain into 54-KD
and 44-I(D fragments, both of which are essential for procoagulant activity. At the same
time, a small fragment is cleaved at Argr68e to dissociate factor VIII from vWT. The
product after these cleavages is the activated factor VIII heterotrimer factor VIIIa, which is
composed of the two heavy-chain fragments and the 72-I<D light-chain fragment (Hoyer,
1994). (Figure 1.3)
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FIGURE 1.2 Structural Domains and Epitope Regions in Factor VIII
The mature factor VIII molecule consists of a number of repeating domains in the order
At(aa r-372)-A2(373-740)-B¡(74r-t689)-A3(r690-2019)-C1(2020-2172)-C2(2113-2332).
The important functional regions in the molecule include the A2 domain (factor IX
binding), as well as the A3 and C2 domains (von V/illebrand factor [vV/F] and
phospholipid [PL] binding, with factor IX binding as well). The red alrows show the
binding sites of factor IX (aa 558-565, 1811-1818), vWF (aa 1649-1689,2248-2312) and
pL(aa 2303-2332) to these functional domains in the factor VIII molecule (major
references: Saenko and Scandella,1995; Saenko et al.,1996; Shima et al.,1995; Zhong et
al., 1998). Epitopes recognised by the inhibitors have been located to the three main
clusters in the A2, A3 and C2 domains, as indicated by the short blue bold lines. aa: amino
acid (residues).











FIGURE 1.3 Gene Organisation and Processing of Factor VIII
(Reprint from Ichinose and Davie. The Blood Coagulation Factors: Their
cDNAs, Genes, and Expression. Hemostasis and Thrombosis: Basic
Principles and Clinical Practice. 3rd Edition. 1993. p. 31.)
Top line represents the Factor VIII gene, showing the 26 exons (vertical bars). Factor VIII
is synthesized as a single-chain precursor with domains AI, A2, B, 43, Cl and C2' On
secretion from the cell, Factor VIII is cleaved into a 200-KD heavy chain and an 80-KD
light chain, apparently held together by calcium ions. The B domain is heavily
glycosylated (HGR, heavily glycosylated region). Shaded regions are rich in acidic
residues. Arrows indicate the cleavage sites (numbered) by proteolysis during the




































2.4 Føctor VIII Gene
The factor VIII gene is 186 kilo base (kb) long (approximately 0.1Yo of the DNA of the X
chromosome) and contains 26 exons and 25 introns. The normal factor VIII mRNA is
approximately 9 kb, of which the coding sequence is 7,053 nucleotides. Deleterious
mutants in the factor VIII gene result in reduction or absence of the factor VIII protein, and
thus cause congenital haemophilia A (Antonarakis et a1.,1995). A database of mutations
in the factor VIII gene was first set up in 1991 and has been updated through the internet
since 1996 (the Haemophilia A Mutation, Search, Test and Resource Site: HAMSTeRS,
accessed via the V/orld V/ide Web at htþ://europium.mrc.rpms.ac.uk). Mutations
described include single base-pair substitutions, deletions, insertions and rearrangements 
in
the gene (Tuddenham et al.,l99l; Tuddenham et a1.,1994; Wacey et a1.,1996; Kemball-
Cook and Tuddenham, 1997).
3. Factor VIII Inhibitors
3.1 Incidence
An exact figure for the prevalence of factor VIII inhibitors is difficult to provide, as the
percentage varies with the population of patients considered, the method used to detect
inhibitors, the threshold level and the frequency and time points at which the detection of
inhibitors are carried out (Gilles et al., 1997). However, it is generally accepted that
inhibitor antibodies to factor VIII develop in 10-20% of patients with haemophilia A, and
more frequently in severe cases, although different studies showed different incidences
ranging from 10% to 45o/o (Aledort, 1996; Berntorp et al., 1995; Brettler, 1995; Furie e/
al.,1994; Gilles et al.,1997; McMillan et a1.,1988; Sallah, 1997)' Overall, the incidence
of inhibitors in patients treated by recombinant factor VIII (TFVII! is similar to that
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observed in patients on plasma-derived factor VIII preparations, despite the fact that some
products did cause much a higher or much lower incidence of factor VIII inhibitors (Bray
et al., 1994: Ehrenforth et al., 1992; Gilles et al., 1997; Lusher et al., 1993; Peerlinck ef
al.,1993).
3.2 Risk Factors
It is important to determine the factors that predispose to inhibitor development- This
would allow investigation of therapies targeted to prevent the establishment of the
inhibitor response or to provide the ability to initiate early immune tolerance induction for
those at a risk.
3. 2. 1 Nongenetic factors
The determination of the risk factors has been the subject of a few studies. There are some
possible risk factors that are considered to be responsible for the development of factor
VIII inhibitors. The nongenetic factors include age, dose and frequency of treatment, and
sometimes the particular type of product, which may be something to do with the
manufacturing processes (Gill, 1999; Berntorp et a|.,1995; Sallah, 1997).
3.2.2 Geneticføctors
More importantly, genetic or familial factors have long been suspected and confirmed to
play a significant role in inhibitor development, in addition to nongenetic factors. In an
analysis of 255 severe haemophilic sib-pairs from 54 centres in North America, there were
more pairs in which both had inhibitors, than was expected. This was interpreted as
supporting the hypothesis that a genetic component to inhibitor formation exists (Gill,
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1999). In a study of 26 mild and moderate haemophilia A patients with inhibitors, it was
also suggested there was a familial predisposition to develop inhibitors in the kindreds
(Hay et a1.,1998). Such a genetic component, however, should be referred to in two parts:
both the factor VIII gene mutation and genetic factors other than the factor VIII mutation.
It is easy to understand that the lack of a recognisable factor VIII protein, as a result of a
particular genetic abnormality,may be the most important determining factor for antibody
formation, as those patients are more likely to see infused factor VIII as a "foreign" protein
and therefore develop antibodies. Several studies have shown that in severe haemophilia
patients, those with large deletions, stop mutations and intrachromosomal recombinations
(intron 22 gene inversion) are more likely to develop inhibitors than those with small
deletions and missense mutations (Schwaab et a\.,1995; Tuddenham and McVey, 1998).
Among these defects, the most common is the gross DNA reaffangement (intron 22 gene
inversion) which has been detected in 45Yo of patients with severe haemophilia A. In this
mutation there is intrachromosomal rearangement of the tip of the long arm of the X
chromosome, with a region within intron 22 of the factor VIII gene (Lakich et al',1993),
which leads to disruption of the gene and absence of factor VIII protein (Lakich et al',
1993). patients with mild or moderate haemophilia, in which there are measurable levels
of factor VIII protein, are much less likely to develop an inhibitor than those with severe
haemophilia (Tuddenham and McVey, 1998), possibly because the infused factor VIII is
not as readily identified as a foreign protein.
However, not all patients with the intron 22 inversion, large deletions, or nonsense
mutations form inhibitors, suggesting that factors other than the factor VIII mutation
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contïibute, such as inherited immune-response characteristics of individuals (Antonarakis
et a1.,I995;Hoyer, lgg4). It has been demonstrated that the risk of inhibitor development
inthe haemophilic sibling of an inhibitor patient is approximately 50o/o, whereas the risk
for an extended family member is only about 10% (Gill et al., 1996). This finding
supports the existence of genetic factors important to inhibitor development, in addition to
any role played by the factor VIII mutation. From the studies available so far, a weak
association of HLA (human Major Histocompatibility Gene Complex, human MHC)
genotype with inhibitor formation has been found (Hay et al., 1997; Oldenburg et al',
I991;Tuddenham and McVey, 1998). In general, studies appear to strongly support the
role of genetic factors in the formation of inhibitors, in addition to the specific underlying
factor VIII mutation, although some researchers still believe environmental factors may be
of the same importance.
3.3 Characteristics of Føctor VIII Inhihitots
Antibodies to factor VIII are immunoglobulins of the IgG class, most commonly the IgG,
isotype, or a combination of two or more subtypes (Fulcher et al., 1987). Occasional
inhibitors that are immunoglobulins of the class A or M have been reported (Gilles et al.,
1997; pruthi and Nichols, 1999). The inactivation of FVIII:C by factor VIII inhibitors is
known to be time and temperature dependent, and is irreversible both in vivo and in vitro
(Hoyer et al., 1984). In addition, factor VIII inhibitors have some degree of species
specificity, especially autoantibodies to human factor VIII, which usually have a much
lower cross-reactivity to porcine factor VIII than alloantibodies (Pruthi and Nichols, 1999).
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The main mechanism of inhibition is thought to be by direct interference with factor VIII
function. Another mechanism proposed, but not with strong evidence, is that of binding to
non-functional regions and increasing the clearance of factor VIII from plasma (l'lilsson e/
a.1., 1990). Both allo- and autoantibodies are found to be directed mainly towards
functional epitopes in the A2 or C2 domains, and inhibit FVIII:C by interfering with
thrombin cleavage, factor VIII-vWF interaction, and factor Vlll-phospholipid binding
(Arai et a1.,1989;Lazarchíck et a\.,1986; Lollar et a\.,1997; Shima et a|.,1993)' Another
study found a third main target region located at the amino-terminal end of the A3 domain,
where the inhibitors are thought to interfere with vV/F binding (Gilles et al.,1993). More
recent studies showed that the inhibition by antibodies against this region may also involve
the delayed release of factor VIII from vWF, and the impaired binding of factor VIII with
factor IX ( Saenko et al', 1996; Zhong et al',1998)'
3.4 Detection of Føctor VIII Antibodies
The Bethesda method is used in the routine laboratory to quantitate inhibitory anti-factor
VIII antibodies (factor VIII inhibitors). It is based on determining the inactivation of
FVIII:C in normal plasma, when incubated with inhibitor plasma under specific conditions
(Kasper et al., 1975; Verbruggen et a1.,1995). One Bethesda unit (BU) is defined as the
amount of inhibitor necessary to neutralise 50olo of FVIII:C in normal plasma during
incubation for two hours at37'C.
Haemophilia patients with factor VIII inhibitors can be divided into two groups, on the
basis of the strength of their inhibitor levels after receiving treatment with factor VIII.
High responders have a strong anamnestic response and the inhibitor titre increases to >10
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BU/ml (or >5 BU/ml according to some researchers), whereas low responders have a much
weaker response and the titre remains <10 BU/ml (or <5 BU/ml) (Berntorp et al., 1995;
Feinstein, 1993; Hoyer, t995; Sallah, 1997). The majority of patients with severe
haemophilia who develop inhibitors are high responders, which makes the management of
such patients very difficult. Most patients with mild or moderate haemophilia A and
patients with autoantibodies to factor VIII are low responders (Sallah, 1997); these
inhibitors may be transient, disappearing spontaneously over time (Brettler, 1995; Ehrlich
et a|.,1998).
In addition to the Bethesda method (based on functional coagulation assays),
immunoassays can be used in research laboratories to detect antibodies to factor VIII
which may or may not inhibit its function. Several methods based on the immunologic
reaction have been developed, including immunoprecipitation, western blot analysis, and
enzyme-linked immunosorbent assay (ELISA) technique (Shurafa and Kithier,1995).
3.5 Kinetic ClassíJication of Factor VIII Inhibitors
There are several ways to classify factor VIII inhibitors, e.9., alloantibodies or
autoantibodies; high response inhibitors or low response inhibitors. Another classical way
to distinguish these inhibitors is by examining the kinetics of their interaction with factor
VIII. It is generally accepted that there are two types of factor VIII inhibitors, classified
according to their kinetic behaviour: type I inhibitors completely inhibit FVIII:C following
second-order kinetics, while type II inhibitors follow more complex kinetics and cannot
completely inhibit FVIII:C (Biggs et a1.,1972 aand b; Feinstein, 1993; Gawryl and Hoyer,
te82).
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Whatever the precise reason for this difference, the distinction between type I and type II
inhibitors remains useful. Type I inhibitors are most often observed in severe haemophilia
A patients who respond to factor VIII infusion by producing high titres of antibodies
(Gilles et al., lg97). In contrast, type II inhibitors are usually observed in mild or
moderate haemophilia A patients, and patients with acquired haemophilia (Gilles et al.,
1997; Hoyer and Scandella,Igg4; Kasper, l99l). In some patients, a mixture of both type
I and type II inhibitors can be found, consistent with the fact that human IgGs are
polyclonal antibodies. It has also been demonstrated that some antibodies behaving as
type I could be converted to type II upon addition of anti-idiotypic antibodies (Gilles et al.,
teeT).
3.6 Treøtment of Inhibitor Patients
Suppressing the production of inhibitors and establishing a state of immune
unresponsiveness to factor VIII remain major goals for the treatment of inhibitor patients'
We are however, far from reaching such goals, basically due to a poor understanding of the
mechanisms underlying specific antibody production and regulation.
Treatment for bleeding episodes by infusion of large doses of factor VIII can be quite
effective in patients with low titres of inhibitors and in patients with recent inhibitors
(Gilles et al.,1997). The therapeutic options for patients with high-titre inhibitors include
the use of materials which bypass the need for factor VIII to allow coagulation, such as
administration of porcine factor VIII, prothrombin complex concentrates (PCC), activated
PCCS (APPCs), and recombinant activated factor VII (Berntorp et a1.,1995; Bloom, 1994;
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Gilles et al.,1997; Sallah, 1997). Usually, a PCC or APCC at a dose of 75 units per kg is
used as first-line treatment for bleeding episodes, although these products are not as
effective as is factor VIII for non-inhibitor patients and cannot be relied upon to prevent or
control bleeding (Berntorp et al., 1995). More recently, human recombinant activated
factor VII has been used with good effrcacy (Hedner et a|.,1993).
Immune tolerance regimes using factor VIII alone or combined with immunosuppressive
drugs (corticosteroids, or cyclophosphamide and intravenous gamma globulin) do have a
reasonable success rate in countries which can afford the protocol. Various immune-
tolerance-induction regimens have been developed and many of them start with large daily
doses of factor VIII. While many patients have had good responses, most appear to require
prophylaxis in order to maintain suppression of their inhibitor antibody. However, it is
strongly recommended that once an inhibitor is diagnosed, immune tolerance should be
considered as soon as possible (Berntorp et al., 1995). Plasmapheresis to remove
antibodies has limited success.
In general, for haemophilia A patients with antibodies against factor VIII, treatment
depends upon the immune response pattern, the antibody titre, and the severity of the
haemorrhagic episode. However, the development of novel and more successful clinical
strategies for the treatment of inhibitor patients is still a big challenge, which requires a
more thorough understanding of the mechanisms by which these inhibitors are formed and
their mode of action.
20
3.7 Acquired Fctctor VIII Inhíbitors
Autoantibodies in patients with acquired haemophilia A have a number of similar
characteristics to the alloantibodies from patients with inherited haemophilia A. For
example, there is a predominance of the IgGo subclass in both groups, in contrast to the
very low (about 5%) proportion of IgGo in normal IgG. In addition, most antibodies from
both groups bind to the A2 andlor C2 domains as revealed by immunological
investigations (Hoyer and scandella,1994 scandella et aL.,1989).
Nevertheless, differences do exist, the most striking one being the pattern of inactivation of
factor VIII by these inhibitors (Hoyer and Scandella, 1994). Most inhibitors in inherited
haemophilia A are type I, in which there is linear inactivation when the logarithm of
residual FVIII:C is plotted against plasma concentration. These antibodies completely
destroy all FVIII:C when present in high concentration. Most inhibitors in patients with
acquired haemophilia have type II properties, where there is non-linear and incomplete
inactivation (Kasper, I99I; Pruthi and Nichols, 1999). Thus, these patients may have a
high inhibitor titre but still maintain some FVIII:C in their plasma.
4.In Vitro Kinetic Study of the Two Types of Factor VIII Inhibitors
The presence of an inhibitor to factor VIII, particularly a high-titre inhibitor associated
with an anamnestic response, greatly complicates treatment. Kinetic studies of factor VIII
inhibitors include experiments to determine the time course of inhibition and to ascertain
the inhibition by various concentrations of inhibitors. These studies may be of importance
in understanding the mechanisms by which these inhibitors interfere with FVIII:C.
possibly such studies may lead to improvements in treatment. In the last few decades,
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some attention has been drawn to this particular basic biological research area of factor
VIII inhibitors.
4.1 Kinetic Features of Factor VIII Inhibitors
The first publications concerned with examining the kinetics of factor VIII inhibitors were
based on case reports of small groups of patients with haemophilia A or acquired
haemophilia (Andersen and Troup, 1968; Biggs and Bidwell,1959; Green, 1968; Kernoff,
I9l2; Leitner et al., 1963; Pool and Miller' 1972; Shapiro, 1967). In these studies,
investigators found an increasing amount of FVIII:C was inactivated by incubation with
increasing concentrations of inhibitor. Biggs and Bidwell (1959), found a linear decrease
of FVIII:C during a two hour incubation with inhibitors from both inherited and acquired
haemophilia patients. All other studies found a curvilinear decline of FVIII:C with
inhibitors from acquired haemophilia patients (Andersen and Troup, 1968; Green, 1968;
Kernoff, 1972; Leitner et a1.,1963; Pool and Miller, 1972; Shapiro, 1967)- However, no
clear idea about the kinetic classification of these inhibitors was formed from these early
publications.
A more extensive study of classification for factor VIII inhibitors was published in 1972by
Biggs et at. (1972 a and b). They described a number of ways in which type I and type II
inhibitors could be differentiated from each other. This was mainly by study of the time
course of factor VIII inactivation. The methodology and its interpretation is complex, and
does not lead to an easy and standardised approach suitable for studies on a large number
of patients. A simpler method which showed differences between the two types of
inhibitors was used by Gawryl and Hoyer (1932). The criteria they used for the
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classification of factor VIII inhibitors was that type I inhibitors can neutralise all (more
thanggo/o) available FVIII:C at high concentrations of inhibitor in a manner consistent with
second-order kinetics, resulting in a linear inactivation response, while type II inhibitors
cannot neutralise alI available FVIII:C even at high concentrations of antibody (Gawryl
and Hoyer, 1982). This seems to be a better way to distinguish type I and type II
inhibitors, as the cut-off value "gSVo" provides a definitive classification.
Since the publications by Biggs et al. (1972 a and b), there has been no detailed study of
methods for the classification of the two types of factor VIII inhibitors' Most of the
subsequent publications have cited their kinetic criteria as generally accepted
(Santagostino, 1995; Hoyer et aI,1984; Kasper, 1984). However, interpretations of their
methodolo gy are complex and inconsistent (Allain and Frommel,l974; Green et al-,1999;
Michiels et aI., 1997; Peerlinck et al., 1997). These problems are further discussed in
Chapter 3.
Other studies have used the time course studies, proposed by Biggs et al. (1972 a and b), to
classify patients in a case-report format (Bovitl et a1.,1985; Gordon et al', 1993; Gordon e/
al., 1994). A type II inhibitor was reported in a mild haemophilia patient, in which there
was incomplete inactivation of FVIII:C in vivo and in vitro (Bovlll et al., 1985). A type I
inhibitor in a severe haemophilia patient was identified by a linear decline of FVIII:C with
time (Gordon et al., 1993). In another study, aiming to assess the therapeutic efficacy of
continuous infusion of a factor VIII preparation for a severe haemorrhage episode, type I
kinetics with a second-order reaction was seen in two patients with inherited haemophilia
A, and one patient with acquired haemophilia. The saturation of the inhibitors was
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achieved after adding an excess of factor VIII concentrate to the inhibitor plasma in vitro
during a time course study (Gordon et al., 1994). None of these studies evaluated the
usefulness of the kinetics studies published by Biggs et al. (1972 a and b). Therefore there
is a need for a detailed analysis of these methods'
4.2 Different Patient Groups with Dffirent Antibody Kinetic Types
Despite the diffrculties in developing a standardised approach to the classification of
inhibitor kinetics, it has become generally accepted that inhibitors in patients with severe
haemophilia A are type I inhibitors, but type II inhibitors have also been observed in this
group (Gilles et al., 1997; Hoyer and Scandella, 1994; Pruthi and Nichols, 1999).
Inhibitors in patients with mild, moderate or acquired haemophilia usually show type II
kinetics, but type I inhibitors have also been described in such patients (Gilles et al',1997;
Hoyer and Scandella, 1994; Kasper, 7991; Pruthi and Nichols, 1999:' Sallah, 1999)'
It seems possible that the kinetics would have a bearing on treatment of the patients. It has
been claimed that it may be useful to know if an inhibitor is type II, since there is always
some measurable FVIII:C in the plasma with these inhibitors (Gawryl and Hoyer,1982). It
could be predicted that patients with type II inhibitors might respond well to infusions of
high doses of factor VIII, while type I inhibitor patients would not (Gilles et al., 1997;
Handin, 1998; Kasper, l99l; Mosher, 1996;Rizza and Biggs, 1973). Conceptually, this
seems reasonable, but to our knowledge there is not any published work to define this.
The hypothesis that patients with type II inhibitors respond better to infusions of high dose
factor VIII is worthy of future investigation. Studies of this nature would require a test
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procedure to differentiate type I and type II inhibitors, which was suitable for use in routine
diagnostic laboratories. It is therefore useful to review the in vitro kinetic studies, and re-
examine the previous complex tests with the aim of designing a procedure which can be
used to differentiate these inhibitors in a routine laboratory. This may provide practical
application to the classification of the two types of factor VIII inhibitors in haemophilia A.
5. Methods to Detect Anti-Factor VIII Antibodies
proper management of haemophilia A patients with factor VIII inhibitors requires accurate
laboratory evaluation. Clotting assays and mixing experiments have been developed and
validated for the reproducible quantitation of factor VIII inhibitors. The most usual assays
in routine laboratories are the New Oxford method (Fiizza and Biggs, 1973) and the
Bethesda method (Kasper et al., 1975), in which a plasma concentrate or a multidonor
pooled normal plasma, respectively, is used as the source of factor VIII. In addition to
these coagulation tests, some immunoassays have been used to detect anti-factor VIII
antibodies which may or may not inhibit the coagulant function of factor VIIL
5.1 ßethesda Assay to Quøntitate Inhibítor Títre
Confirmation and quantitation of a factor VIII inhibitor in a patient with haemophilia A is
established in routine coagulation laboratories by performance of the Bethesda assay. This
assay has been a conssnsus method for clinical evaluation of factor VIII inhibitors since its
first description in 1975 (Kasper et al., 1975), and is a uniform method widely used in
routine diagnostic laboratories. In this assay, the reaction mixture is incubated for two
hours at 37"C, because these inhibitors are not usually fast-acting and are temperature-
dependent. The Nijmegen modif,rcation has since improved the specificity and reliability
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by preventing pH drift, which if uncontrolled, causes deterioration of factor VIII hence
false positive results (Verbruggen et al.,1995; Giles e/ al.,1998; Ehrenforth et al.,1992).
Briefly, test plasma containing factor VIII inhibitots, or factor VIII deficient plasma as a
control, is incubated at 37oC for two hours with an equal volume of buffered pooled
normal plasma. The residual FVIII:C in both the test and control samples is then
determined by one-stage factor VIII assay. The inhibitor titre is expressed in terms of
Bethesda units (BU), where a test sample resulting in a residual FVIII:C of 50Vo of the
control is considered to have one Bethesda unit of inhibitor per millilitre (BU/ml)
(Goldsmith,1993; Luddington and Jennings,1992; Verbruggen et al.,1995; White, 1994).
The limit of detection by this method is generally agreed to be 0.5 BU/ml of factor vIII
inhibitor in plasma.
It should be recognised that there are limitations to the Bethesda assay in that it is restricted
to analysis of antibodies directed against functional epitopes, and it is unable to detect non-
inhibitory antibodies which may significantly influence plasma clearance and survival
times of infused factor VIII (Gilles et al., 1993; Dazzi et al., 1996; Regnault and Stoltz,
L994: 'White, l9g4). Fulcher et at. (1985) originally reported one patient in their series
with an antibody that recognised an epitope in the B domain of factor VIII, a region not
necessary for procoagulant activity. In a study by Gilles et al. (1993), the majority of anti-
factor VIII antibodies detected by an immunoblotting assay did not interfere with its
function. Antibodies recognising non-functional regions on factor VIII may be an
explanation for the shortened factor VIII survival observed in some patients who do not
have antibodies detected by the Bethesda assay. Thus the evaluation of anti-factor VIII
antibodies solely by a functional method may not provide an accurate evaluation of the
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speciflc antibody response. Low-level inhibitory antibodies and antibody-factor VtrII
complexes may also not be detected in the Bethesda assay, but this is a theoretical problem
without supporting evidence (White, 1994).
5.2 ELISA Method to Detect Anti-Factor VIII Antibodies
To improve the detection rate of antibodies, immunoassays, which measure both inhibitory
and non-inhibitory antibodies based on their immunologic reaction with factor VIII
molecules, have been proposed as alternative methods. These immunoassays include
immuno-neutralisation, immunoprecipitation, immunoblotting analysis, and ELISA
techniques, including a novel adoption, the so-called antigen-containing strips method
(Fulcher et a1.,1985; Nilsson et a\.,1990; Sanchez-Cuenca et al., 1990; Scandella et al.,
1998; Shurafa and Kithier, 1995).
ELISA is the abbreviation of Enzyme-Linked ImmunoSorbent Assays and can be used to
measure antibody titre. The antigen of interest is directly adsorbed onto a solid substrate.
A primary unlabelled antibody, derived from blood or any other body fluid, binds to the
antigen on the solid substrate. A secondary antibody, to immunoglobulin of the species of
the primary antibody, is conjugated to an appropriate enzyme. When the substrate is
added, a colour change develops, the intensity of which is proportional to the amount of
primary antibody bound to the antigen.
For detection of factor VIII antibodies in patients, the patient plasma is used as the primary
antibody. Early studies on the ELISA method to detect factor VIII antibodies in
haemophilia patients were described in 1990, with one study proposing this method to be
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simple, accurate and highly sensitive for immunological characterisation of factor VIII
antibodies (f{ilsson et al., 1990; Sanchez-Cuenca et al., 1990). Subsequent reports have
demonstrated the use of highly purified factor VIII, which is adsorbed onto microtitre
plates, with a peroxidase-conjugated goat anti-human IgG antibody for ELISA detection of
factor VIII antibodies (Gautier et a1.,1996; Mondorf et aL,1994). The results suggest that
ELISA may be a suitable complementary test to the Bethesda assay for factor VIII
antibody screening in haemophilia and non-haemophilia patients, although it cannot be
used instead of the coagulation tests (Gautier et al., 1996; Mondorf et a1.,1994; Regnault
and Stoltz, 1994).
The possibility of measurement of both inhibitory and non-inhibitory antibodies by ELISA
was suggested in a study in which all 18 patients with allo- or auto- antibodies to factor
VIII (inhibitor activity from 1 to 5,500 BU/ml) exhibited clear positive reactions, while
none of the normal plasma results were positive (Regnault and Stoltz, 1994). The authors
suggested that inhibitor activity as low as 0.1 BU/ml would be clearly detected by means
of their test. In 1996, an Italian research group using recombinant factor VIII as the
coating antigen showed a high prevalence (41%) of non-inhibitory antibodies in a group of
23 haemophilia patients whose inhibitor titres were undetectable by Bethesda assay (Dazzi
et a|.,1996).
The same research group subsequently reported that 8lo/o of patients with the intton 22
inversion were found to have factor VIII antibodies by ELISA, compared with only 35%
for those without the inversion. This implied that the intron 22 gene inversion is a major
predisposing factor for the development of factor VIII antibodies (Vianello et al., 1997).
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The inhibitor prevalence revealed by the Bethesda assay in this study was 25Yo and ITYo
for patients with and without the inversion, respectively (Vianello et al.,1997). Disruption
within intron 22 of the factor VIII gene has been found to be the causative mutation in 50o/o
of patients with severe inherited haemophilia A. In this mutation there is
intrachromosomal reaffangement of the tip of the long arm of the X chromosome, with a
region within intron 22 of the factor vIII gene (Lakich et a|.,1993).
The presence of factor VIII inhibitors in severe haemophiliacs with this gene inversion has
been extensively evaluated. This is because patients with such a major gene defect are
thought most likely to see factor VIII as a "foreign" protein and therefore develop
inhibitors, as there is little or no circulating factor VIII in their plasma. In addition, the
intron 22 gene inversion is a common mutation which is readily detected. The prevalence
of factor VIII inhibitors reported in these patients ranged from 0% (0/10, Goodeve et al.,
lgg4) to yt%o (13116, Vianello et al., 1997), including 25% (5120, Ljung, 1994), 36%
(13136, Tizzano et al., lg94),31.5% (18/48, Tizzano et al', 1995) and 42.4Yo (25159,
Schwaab et al., 1995) in six individual studies. In addition, results from an international
consortium, combining data ftom 642 patients with the inversion, indicated that 20o/o of
them developed factor VIII inhibitors (Antonarakis et al., 1995). In general, it is now
strongly believed that there is a definite correlation between the intron 22 gene inversion
and the presence of factor VIII inhibitors, with data confirming the prevalence of inhibitors
in these patients higher than for haemophilia in general. However, in severe haemophilia
A, the proportion of patients with inhibitors in the subgroup of intron 22 gene inversion
should not be different from that in the subgroup of other major gene mutations, such as
large deletions, and point mutations resulting in stop-codons or frame shifts.
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6. Epitope Detection on Factor VIII Peptides
Although the anti-factor VIII immune response is clearly polyclonal, inhibitors tend to
cluster to a few regions (Gilles et al.,1997). Since the mid-8O's, Fulcher, Scandella and
co-workers have been making progress in localising factor VIII epitopes using a variety of
immunological and molecular approaches (Hoyer, I99I)'
The mature factor VIII molecule is a single-chain protein made up of 2332 amino acid
residues, which consist of a series of domains arranged in the order A1-42-B-43-CL-C2'
Specific cleavages at amino acid positions 372,740 and 1689 of the mature protein yield
an active heterotrim er of 54, 44 and 72 lA subunits (Figure 1.3). There are a number of
regions in factor VIII which act as epitopes for inhibitors. However, the A2 domain (44
KD fragment from the heavy chain) and the C2 domain (segment on the 72 KD fragment
of the tight chain) of factor VIII contain the epitopes targeted by most (90%) inhibitory
antibodies (Lubin et al., 1994; Scandella et al., 1989; Scandella et al., 1992). More
precisely, the majority of antibodies are directed towards a 17 .3 KD segment located at the
carboxy-terminal end of the C2 domain and/or towards a 18.3 KD segment located at the
amino-terminal end of the A2 domain (Scandella et al., 1988). In addition, patients may
have multiple antibodies against multiple sites on the factor VIII molecule (Hoyer, 7991;
Scandella, 1995). (Figure 1.2)
Immunoblotting of thrombin-cleaved factor VIII was used as the first approach to localise
epitopes for anti-factor VIII antibodies in inhibitor plasmas. In one study by Fulcher et al.
(1985), antibodies bound to either the 72 KD (light chain) or the 44I<D (heavy chain), or
both. Using immunoblotting of deletion polypeptides expressed in Escherichia Coli (8.
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Coli) (V/ood et a1.,1984), these epitopes were localised to amino acid residues322-372
between the Al and A2 domains, 373-541 at the amino terminus of the A2 domain, and
2173-2332 of the C2 domain.
Later epitope mapping studies have shown the binding site for inhibitors to be much
smaller fragments of factor VIII, such as residues 484-508 in the A2 domain and residues
2303-2332 in the C2 domain (Healey, 1995; Scandella et al., 1995 a). In addition, there
are some studies showing that inhibitory epitopes may localise to the A1 domain or to
somewhere uncertain within the light chain, but outside the C2 domain, e.g., the A3
domain (Gilles et al., 1993; Lollar, 1997; Scandella, 1996; Scandella et al', 1989).
Recently, residues 1804-1819 of the A3 domain were identified as an epitope region,
which comprises a binding site for factors IX and IXa (Zhong et a1.,1998). Methods used
to perform epitope mapping include using thrombin-cleaved fragments of factor VIII,
recombinant factor VIII segments, and various immunoassays such as immunoblotting,
immunoprecipitation, ELISA and immunoneutralisation assays.
Work which has been performed to detect the epitopes in factor VIII has built up data
about the regions of the factor VIII molecule involved in antibody binding. More studies
need to be done to further localise the epitopes to smaller peptide fragments, i.e', 20 amino
acids, for the purpose of possible therapeutic application in the future, namely, the
neutralisation of the inhibitory function of factor VIII inhibitors by infusion of epitope-
containing peptides to bind to the inhibitors in vivo'
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7. Aims of the Project
There is increasing knowledge concerning the mechanisms of and sites of action of
inhibitors of factor VIII. For instance, the kinetics of the inhibitors in severe inherited
haemophilia A tend to be different from those in mild inherited haemophilia A and
acquired haemophilia A. Major functional epitopes for these inhibitors have been
described and the pattern of binding may also differ in the different patient groups of
haemophilía A, such as inherited severe, inherited mild, and acquired. There is also
evidence that antibodies may be directed against non-functional epitopes. There is little or
no knowledge concerning whether the epitope sites are related to the type of mutation in
inherited haemophilia. To further develop our ability to explore these aspects it was
planned to study the kinetics of action of inhibitors in a group of patients with inherited
and acquired haemophilia A. Ho\,vever, the methods described for the characterisation of
the kinetics of factor VIII inhibitors are complex, and interpretations in the literature are
contradictory. In addition we planned to explore the possibility that our patients with
haemophilia A might have inhibitors that bind to non-functional sites on factor VIII. A
further project was to develop methods to detect binding of inhibitors in our patients to the
known functional epitopes on the factor VIII molecule.
Therefore the overall aims of this thesis were:
1. To evaluate the available methodology for characterising the kinetics of factor VIII
inhibitors.
2. To charucterise the kinetics of factor VIII inhibitors in a group of our patients
3. To explore the possibility that there may be inhibitors that bind to non-functional
epitopes
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4. To detect inhibitor binding to epitopes in the A2 and C2 domains of factor VIII.
These aims are part of a broader long term strategy of our department which is to explore
the relationships between the epitope sites for these inhibitors, the kinetics of their action,
and the nature of the haemophilia. This includes the relationship to whether ttry





1. Patient and Control Samples
1.1 Pøtients
Most of the patients, including patients with inherited haemophilia A and acquired
haemophilia A, were from the South Australian Haemophilia Centre at the Royal Adelaide
Hospital, and the Adelaide Vy'omen and Children's Hospital. Plasma from the remaining
patients was kindly supplied by Dr. Alison Street from the Alfred Hospital in Melbourne,
Victoria.
To ensure plasma factor VIII levels were at baseline, blood samples were usually collected
at least seven days after the administration of any factor VIIII therapy. However, for
children who receive prophylaxis therapy three times a week, samples were collected just
prior to a dose of factor VIII. Most samples were taken within the last three years, while
the earliest sample was obtained in 1988
1.2 Sample Preparatíon
Blood samples were collected into 1/l0th volume 109mM trisodium citrate anticoagulant.
Plasma and cells were separated by centrifugation at 3,000 rpm (2,000 g) in a Beckman J-
68 centrifuge for l0 minutes at l5-20"C. Plasma was transferred to into a clean tube and
re-centrifuged for another 10 minutes at 3,000 rpm. The supernatarÍ, free of platelet
contamination, was then removed and stored at -70"C for measurement of factor VIII
parameters. Plasma samples were kept at 4"C during transport when applicable
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Prior to inhibitor testing, plasma samples were heated at 56"C for 15 minutes to destroy
FVIII:C which could interfere with the calculation of residual FVIII:C in the test
incubation mixture (Lloyd et al., 1997). After this heat inactivation, samples were
centrifuged 1-2 minutes in an Eppendorf tube in a microfuge at 13,000 rpm to remove any
precipitated protein.
1.3 Normal Plasmø Used in ELISA Assay
Blood samples from normal donors were kindly provided by the Red Cross Blood
Collection Centre. Plasma preparation was the same as described above. These samples
were used for the control group for the detection of factor VIII antibody by ELISA.
2. Materials
2.1 Bethesda Assay ønd Modiftcations for Kinetic Studies
2. 1. I Commercial reagents
Factor VIII Deficient Plasma: Factor VIII Deficient Plasma from Organon Teknika
Corporation (Durham, USA): 10 vials/l.0 ml each; Product Number 38920; Lot Numbers
103963, 161 180, 16120l, 1 10910, 1 10928, 110944, 1 10945.
Coagulation Reference Plasma: Coagulation Reference Plasma Normal from Realm
Biomedical (Brisbane, Australia): 10 vials/l.O ml each; Product Number CRP-N; Lot
Numbers 401!, 4012,4013. (Calibrated against World Health Organisation International
Rederence Plasma.)
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Quality Control Plasma: Dade@ Ci-Trol@ Coagulation Control, Level I from Dade
International Inc (Miami, USA): 10 or 20 vials/l.0 ml each; Product Number 84244-10;
Lot Numbers 825, 1013. (Factor VIII values for mean and2 SD (standard deviation) range
were established in-house.)
APTT Reagent: Dade@ Actin@ FSL Activated PTT Reagent from Dade Behring
(Marburg, Germany): 10 vials/l0 ml each; Product Number 84219-2; Lot Numbers 156,
202A,527308
Factor VIII Concentrate: AHF (High Purity) from CSL Limited (Parkville, Australia): 250
IU/vial reconstituted in 10 ml injection water; Product Number R 29767; Lot Number
L31100185D.
2.1.2 Buffers and solutions
Owren's Buffer pH 7.35: 5.88g sodium dietþlbarbiturate and 7.34g sodium chloride in 1
litre distilled water, adjusted pH 7.35.
Calcium Chloride 25mM: AnalaR@ calcium chloride solution lM stock (BDH, Production
Number 19046) diluted ll40 insterile water
Imidazole Solution 5.0M:680mg imidazole salt in 2 ml distilled water
Hydrochloric Acid Solution lN (IN HCI):32o/o stock HCI (8.6 Normal/Molar) diluted 1/8.6
in distilled water.
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Buffered, Pooled Normal Plasma (B-PN): To 1 ml pooled normal plasma (Batch Number
PN38), 20 ¡i imidazole solution (5M) was added to bring the solution to 0.lM imidazole,
and pH was adjustedto 7.4 with lN HCI (28 prl per ml plasma).
2.1.3 Equípment
MLA Electra 1000C (Medical Laboratory Automation, Inc., New York, USA) automatic
coagulation analyser: used to perform one-stage FVIII:C assays according to the operator's
manual. Sample cups and cuvettes were also supplied by MLA.
2.2 IgG PuriJicationfrom Plasma
2.2.1 Purffication kit snd concenttation column
The ImmunoPure@ (G) IgG Purification Kit was purchased from Pierce Chemical
Company (Rockford, USA); Product Number 44441; Lot Numbers 97041168, 98010765,
990r21601-.
Two products from Amicon, Inc. (Beverley, USA) were used: centrifugal filter device
Centriprep@ YM-10 (for larger volume of concentration); Product Number 4304; Lot
Number L8PM9235D, and centrifugal filter device Centricon@ YM-I0 (for small volume
of concentration); Product Number 4205.
2.2.2 Buffers
The following buffers were used:
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1. ImmunoPure@ (G) IgG Binding Buffer from Pierce Chemical Company (Rockford,
USA), 3.75 litres; Product Number 2I}llAD; Lot Number 981 1670.
2. ImmunoPure@ IgG Elution Buffer from Pierce Chemical Company (Rockford, USA), 1
litre; Product Number 2I004AD; Lot Number 98122362.
3. Phosphate Buffered Saline (PBS) pH 7.4: 8g NaCl, 0.2g KCl, 2.279 NarHPOo
(anhydrous), and O.2gKÍIrPOo in 1 litre distilled water, adjusted to p}J7.4.
4. PBS p}J7.4 - 0.1% Tween: 1 ml Tween 20@ (Sigma) in 1 litre PBS pH7.4.
2.2.3 Optical Density (OD) detection
WPA (Cambridge, UK) Biotech Photometer UVl101 (Series Number 3052) was used to
measure OD at 490 nm
2.3 ELISA Method to Detect Factor VIII Antibody
2.3. 1 Commerciul reøgents
2.3.1.1 Factor VIII Source to Coat Microtitre Plate
Formulated recombinant factor VIII produced by Baxter Healthcare Corporation
(Deerfield, USA) RecombinaterM: 500 lU/vial reconstituted in 10 ml water for injection;
ProductNumber Ft49620; LotNumber 2938M55148. (Purchased from CSL Limited.)
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Unformulated recombinant factor VIII, a generous gift from Baxter Healthcare
Corporation: 0.21 mglm|1400 IU/ml reconstitutedin2 ml injection water; Lot Number
1A03L003
2.3.1.2 Monoclonal Primary Antibody
(murine) Monoclonal Antibodies Against Human Factor VIII:C from American
Diagnostica Inc. (Greenwich, USA); Product Number ESH 8; Lot Number 99052I.
2.3.1.3 Secondary Antibody
Peroxidase-Conjugated Rabbit Anti-Mouse Immunoglobulins from DAKO A/S (Glostrup,
Denmark); Product Number P 0260; Lot Number 016 (102).
Peroxidase-Conjugated Rabbit Anti-Human IgG, Specific for Gamma-Chains from DAKO
A/S; Product Number P 0214; Lot Numbet II5 (202)
2.3 .I .4 1,2-Phenylenediamine Dihydrochloride (OPD' 2HCl, OPD) Solution
OPD Tablets,2 mg For ELISA from DAKO A/S; Product Number S 2045; Lot Number
108 (101). Each tablet containing 3.5 mg OPD'2HC1 corresponding to 2 mg OPD. 2
tablets dissolved in 6 ml 0.lM Citric Acid - Phosphate Buffer pH 5.0, and added with2.5
pl30% Hydrogen Peroxide (HrOr).
2.3.2 Buffers
coating buffir (0.1M carbonate Buffer pH 9.6): 2.939 NaHCO, and 1.599 NarCO,
(anhydrous) in I litre sterile water to dilute factor VIII.
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Washing buffer (PBS pH 8.0 - 0.1o/o Tween): 8g NaCl, 0.2g KCl, l.l4g NatHPOo
(anhydrous), and 0.2g KHTPO. in I litre sterile water, adjusted to pH 8.0, with 1 ml Tween
20@ (Sigma) added.
Blocking buffer (PBS - Tween - 0.5% Gelatin):0.5g Gelatin (Sigma) added to 100 ml PBS
pH 8.0 - 0.1% Tween, dissolved at37"L.
0.1M Citric Acid - Phosphate Buffer pH 5.0: 1.469 Citric Acid.HrO and 2.3749
NarHPOo.2HrO in 200 mI sterile water, adjusted pH 5.0
2.5M H2SO4: l9}l4 stock H2SO4, diluted ll7 in sterile water
2.3.3 Equipment
Nunc A/S (Roskilde, Denmark) microtitre plates Nunc-ImmunorM Module Cl2
MaxiSorprM Surface; Product Number 473709; Lot Numbet 046654.
Dynatech Laboratories (Chantilly, USA) microplate reader MR 7000 (Series Number
G099S) was used to read the OD at 490 nm.
2.4 Epitope Detection on FacÍor VIII Peptide
2.4.1 Recombinant DNA technology to producefactor VIIIfTøgments
2.4.I.I. Commercial Products
DNA polymerase with buffer:
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Roche Molecular System, Inc. (Branchburg, USA) AmpliTaq GoldrM (250U, 5U/pl), with
GeneAmp@ 10X PCR Buffer II & MgCl, Solution; Product Number N808-0241.
Boehringer Mannnheim (Alameda, USA) Expand High Fidelity PCR System (100U) , with
Expand HF buffer, l0Xconc. with 15 mM MgClr; Product Number I 732 641.
Polymerase chain reaction (PCR) products purification kit: Bresatec Pty. Ltd. (Thebarton,
Australia) BRESAspinrM PCR Purification Kit (100); ProductNumber BT-2000-100.
Gel extraction kit: QIAGEN Pty. Ltd. (Clifton Hill, Australia) QlAquick Gel Extraction
Kit (50); ProductNumber 28704.
Restriction enzyme: Pharmacia Biotech (Uppsala, Sweden) BamH I IG.LGATCC] (2,000
units); Production Number 27-0868-03.
Vector: Phamacia Biotech (Uppsala, Sweden) Glutathione S-transferase (GST) Gene
Fusion Vector pGEX-2TK (25VÐ; Product Number 27-4587-01
DNA ligation enzyme: New England Biolabs (Beverly, USA) T4 DNA Ligase 2023
(20,000 units, 400,000 U/ml); Product Number 66.
DNA molecular weight marker; Bresatec Pty. Ltd. (Thebarton, Australia) SPPl/EcoRI
DNA Molecular Weight Marker (100pg); ProductNumber DMW-SI.
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Isopropyl-beta-D-thiogalactoside (IPTG): Progen Industries Limited (Darra, Australia)
IPTG (1 g); Product Number 200-0120.
Protein purification resin'. CLONTECH Laboratories, Inc. (Palo Alto, USA) TALON@
metal affinity resin (10 ml); Product Number 8901-1'
2.4.1.2 Buffers
5 X TBE buffer:216g Tris base 7 -9 (Sigma) , I 10g Boric Acid, and 80ml EDTA (0.5M, pH
8.0) in 4 litres of deionised water.
Colony cracking solution:50 pl NaOH (1M), 50 ¡i I0% Sodium Dodecyl Sulphate (SDS),
10 ¡rl EDTA (0.5M), 80¡rl Glycerol, 810 pl sterile water, and the stain powder
(bromophenol blue) to make 1 ml.
4 X separating gel buffer:37.4g Tris base 7-9 (Sigma) and 8 ml lÙYo SDS in 175 ml sterile
water, adjusted to pH 8.8, then made up to 200 ml'
2 X protein loading buffer:2 ml Tris-HCl (0.5M) pH 6.8, 1.6 ml Glycerol, 3.2 ml IlYo
SDS, 0.8 ml2-p-mercaptoethanol, 0.4 mI0.05% bromophenol blue in sterile water to make
8 ml.
Lysis buffer:2.5 ml NaHrPOo (1M), 500 ¡rl Tris (1M), 24gUtea, and 5 ml NaCl (1M) in 40
ml sterile water, adjusted to pH 8.0, then made up to 50 ml.
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Protein elution buffer:200 ¡rl Tris-HCl (lM) pH 8.0, I ml NaCl (1M), 4.8g Urea, 1 ml
Imidazole (2M), and 400 pl MES (2-[N-morpholino] ethane sulfonic acid) (0.5M) in sterile
water to make 10 ml, adjusted to pH 5.3.
2.4.1.3 PCR Equipment
Perkin Elmer Corporation (Norwalk, USA) Perkin-Elmer Cetus DNA Thermal Cycler
Perkin Elmer Corporation (Norwalk, USA) Perkin-Elmer DNA Thermal Cycler 480
2. 4. 2 lles te r n b lot w ith th r o mb in- c le uv e d fac t o r VI I I fr a g ments
2.4.2.1 Thrombin Cleavage Reagents
Factor VIII sources: RecombinaterM (50 IU/ml) and Baxter unformulated factor VIII (1400
IU/ml) as previously described (see section 2.3.l.l).
Thrombin: Diagnostica Stago (Asnieres-sur-Seine, France) citrated calcium thrombin
(human) STA@ - ThrombinØ (stock concentration 3 NIH unilml); Product Number
00611; Lot Number 973512
Reducing buffir: Pierce Chemical Company (Rockford, USA) ImmunoPure@ Lane Marker
Reducing Sample Buffer; Product Number 39000; Lot Number AD40446.
2.4.2.2 Protein Electrophoresis
7.5oÁ acrylamide gel made up of:
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Milli Q water
4 X Stacking buffer
4 X Separating buffer
40Yo acrylamide
TEMEDÍ













f : N'N'N'N'-Tetramethylethylenediamine, ultra pure grade (Amresco).
Protein lane mqrker: Life Technologies, Inc. (Gaithersburg, USA) BenchMarkrM
Prestained Protein Ladder; Product Number 10748-010; Lot Number 1030096. Protein
loading buffer: ImmunoPure@ Lane Marker Reducing Sample Buffer as described before
(section 2.4.2.1).
10 X SDS-PAGE (polyauylamide gel electrophoresis) running buffer: 30g Tris base 7-9
(Sigma), l44gGIycine, and 10g SDS in I litre distilled water.
2.4.2.3 Membrane Transfer
Semi-Dry transfer buffer:2.9g Tris base 7-9 (Sigma), 1.45g Glycine dissolved in - 350 ml
distilled water, add 100 ml methanol and 1.85 ml 10% SDS, and make up to 500 ml.
Nitrocellulose membrane: Advantec MFS, Inc (Pleasanton, USA) Membrane Filters
Cellulose Nitrate; Product Number 40454330R; Lot Number B27I(j
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Semi-Dry transfer unit: Hoefer Pharmacia Biotech Inc (San Francisco, USA) SemiphorrM
Transphor; Hoefer@ Number TE l0; Product Number 80-6210-34; Series Number
20039555.
2.4.2.4 Blotting and Probing
Blocking buffer: 5% Skim Milk in PBS pH 7 -4 -0'l% Tween'
Antibody dilution buffer:2.5% Skim Milk in PBS pH 7.4 - 0.1% Tween.
primary antibodies: Harlan Sera-Lab Limited (Loughborough, England) MAS 530 -
Monoclonal mouse anti-human factor VIII heavy chain; Product Number MAS 530p; Lot
Number PC96L530. Harlan Sera-Lab MAS 531 - Monoclonal mouse anti-human factor
VIII heavy chain; Product Number MAS 53lp; Lot Numbet P92C53l-2- ESH 8
(American Diagnostica) as described before.
Secondary antibodies: Amersham Pharmacia Bitotech UK Limited (Buckinghamshire,
England) Anti-mouse IgG, peroxide-linked species specific F(ab'), fragment (from sheep);
Product Number NA 9310; Lot Number 144832. Amersham Anti-human IgG, peroxide-
linked species-specific whole antibody (from sheep); Product Number NA 933; Lot
Number 148927.
Enhanced Chemiluminescence (ECL) detection reagents: Amersham Pharmacia Bitotech
UK Limited (Buckinghamshire, England) ECL@ 'Western blotting detection reagents;
Product Number RPN 2109; Lot Number 61.
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ECL film: Amersham International plc. (Buckinghamshire, England) high performance
chemiluminescence f,rlm HyperfilmrM ECLrM; Product Number RPN 3103H; Lot Number
07020270215.
3. Methods
3.1 In Vitro Kinetics of Føctor VIII Inhibitors
3.1.1 Bethesdø assay to quøntitate FVIII:C inhibitors
Factor VIII:C inhibitors were measured using the Nijmegen modification (Verbruggen et
at., 1995) of the Bethesda method (Kasper et al., 1975). Haemophilia plasma (test) or
factor Vlll-deficient plasma (control) was incubated with an equal volume of buffered,
pooled normal plasma @H7.4) for two hours at 37"C in a closed plastic tube. Remaining
FVIII:C (IU/ml) was measured by one-stage assay (Mannucci and Tripodi, 1992) and
Residual FVIII:C (%) expressed as a percentage of the control'
The strength of an inhibitor for a patient plasma is estimated from a graph, in which the log
of residual FVIII:C (%) is plotted against the Bethesda units on a linear scale. For the
estimation to be valid, the percentage of residual FVIII:C must be in the linear region of
the graph between 25o/o and 75Yo of control FVIII:C. If residual FVIII:C >75o/o, the
inhibitor is reported as not detected. The test plasma must be further diluted and retested if
residual FVIII:C is less than 25Yo. The inhibitor titre for a test plasma is calculated as the
Bethesda units from the graph multipled by the plasma dilution tested. An inhibitor with
one Bethesda unit per ml is defined as the amount of antibody causing 50olo reduction in
FVIII:C compared to the control incubation.
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In this study, investigations of kinetics used variations of the basic method for the Bethesda
assay. Modifications made included incubation time, antibody concentrations, and the
initial factor VIII levels. In general, results were expressed as residual FVIII:C as a
percentage of the control value, although the actual FVIII:C remaining is given in selected
experiments
3.1.2 Time course studies
Patient plasmas were incubated for two or four hours, in a small capped tube, with pooled
normal plasma. Aliquots were removed at 0 minute, l5-minute, and then at 30-minute
intervals until the end of the experiment. The amount of the remaining FVIII:C (IU/ml) at
each time point was measured and the percentage of the control was calculated. The
logarithm of residual FVIII:C (%) was plotted against the incubation time in a semi-
logarithmic graph and was referred to as a "time curve" in this study.
3. 1.3 Antibody concentrøtion studies
A series of dilutions of patient plasma in factor Vlll-deficient plasma was incubated with
an equal volume of pooled normal plasma for two hours at 37'C and the remaining FVIII:C
(IU/ml) was measured and the residual FVIII:C (o/o) calculated. The logarithm of residual
FVIII:C (%) was plotted against the logarithm of antibody dilution, and was referred to as a
"concentration curve" in this study.
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3.1.4 Purijicatìon of IgGfrompøtient plasmø
This was done to enable dilution curves to be determined in plasmas with low-titre
inhibitors. Ten ml patient plasma was added to an immobilised protein G column and IgG
was separated from other plasma components according to the manufacturer's instructions
(ImmunoPure@ IgG Purification Kit, Pierce). The eluents containing the greatest amounts
of IgG (as shown by OD reading at 280 nm) were then pooled and concentrated by
centrifugation using centrifugal filter devices according to the manufacturer's instructions
(Centriprep@ 10 and Centricon@ 10, Amicon). The small volume (less than 500 pl) of
concentrated IgG in buffer was used in antibody dilution studies to give a higher level of
inhibitor titre.
3.1.5 Effect of extra source offactor VIII
Extended time courses were done to study the ability of bound antibodies to inhibit
additional factor VIII (Bovill et al., 1985). Patient plasma was diluted in factor VIII-
deficient plasma and incubated with factor VIII concentrate (AHF) (approximately 1.0
IU/ml in the mixture) for four hours, after which an additional amount of AHF was added
to the mixture for another two or four hours incubation. The control mixture was made up
of AHF with factor Vlll-deficient plasma. Remaining FVIII:C (U/ml) was measured for
aliquots of the mixture every two hours, and plotted against the incubation time.
3.1.6 Effect of the ínitialføctor VIil concentration
This experiment was designed to clarify the effect of the critical concentration ratio of
antigen to antibody in the reaction mixture. A series of dilution curyes of patient plasma
with different initial factor VIII concentrations was studied. In addition to using undiluted
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pooled normal plasma in the incubation mixture, pooled normal plasma was diluted 2 in3,
I in2, and I in 4 in factor Vlll-deficient plasma. Residual FVIII:C (%) for each antibody
dilution was plotted on a logarithmic scale against the initial factor VIII concentration
(IU/ml).
3. 1.7 Mathematic ønalysis
The results of the time course studies and antibody concentration studies were analysed
using the statistical program GraphPad Prism version 3.00 for 'Windows 95 and NT,
GraphPad Software, San Diego California USA, www.graphpad.com. Reaction models
were chosen trying to distinguish the two different types of kinetic data in a mathematical
way.
3.2 ELISA Method to DetectAnti-Factor VIII Antibodies
Microtitre plates Nunc-ImmunorM Module MaxiSorprM were coated with 50 pllwell factor
VIII (RecombinaterM or Baxter@ unformulated factor VIII) in coating buffer, covered and
incubated at 4"C overnight. After flooding the plates with washing buffer six times the
next day, uncoated sites were blocked by adding plates with 100 ¡rl/well of blocking buffer
for 90 minutes at room temperature. Plates were washed again and primary antibody,
diluted in blocking buffer, was added (50 pllml), then incubatedat room temperature for
two hours. A series of appropriate antibody dilutions were used, both for the murine
monoclonal antibody ESH 8 and the plasmas from normal blood donors and haemophilia
patients. After washing, the secondary antibody which was either rabbit anti-mouse or
rabbit anti-human IgG with HRP (horse radish peroxidase) was incubated for one hour (50
pl/well, 1/4000 dilution of stock in blocking buffer, representing a saturating
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concentration). Substrate (OPD solution) for the HRP-linked enzyme was then added and
the colour reaction allowed to process for 10 minutes before H2SO4 (50 ¡rl/well) was added
to stop it. OD readings (at wavelength of 490 nm) were made after f,rve minutes by
Dynatech microplate reader MR 7000.
3.3 Epitope Detection on Føctor VIII Peptide
3.3.1 Recombínant DNA technology using bacterial expression system to produce factor
VIIIfTøgments
The following was the procedure used in attempts to produce recombinant Al fragment.
Attempts to produce heavy chain, AllA2, and A2 fragments were also performed during
the research period of this project. Hov/ever, none of them had achieved any successful
result, despite the large amount of work and time spent. This suggests that there is still a
lot to be done on the methodology development. This work was performed in conjunction
with a current research project carried out in the Molecular Pathology Division at IMVS.
The method and results following show parts of the work I undertook. The principle used
to produce the A1 domain can be applied to other segments of factor VIII.
3.3.1.1 PCR to Make Target Gene
The gDNA (copy DNA) corresponding to the region encoding the factor VIII Al domain
was amplified by a PCR, with primers designed, to insert the BamHl restriction enzyme
site at both the 3'- and 5'- ends of the oligonucleotide chain. The Al target gene starts from
theHlT2 (heavy chainNo. 172 base pair) and finishes at H1375 (heavy chainNo. 1375
base pair) and the length of gene is -1.3 kb. The base pair sequence recognised by BamHI
restriction erayme is "GJ,GA TCC". Therefore, the primers used in this PCR reaction
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were designed to be as follows: the 5' primer (HI72 BamH I, forwards) GAT GGA TCC
ATG CAA ATA GAG CTC TCC ACC; and the 3' primer (H1375 BamH I, backwards)
GCG GGA TCC CCA AGT TTT AGG ATG CTT CTT. The primers were purified and
pre-checked with AmpliTaq GoldrM (Roche) PCR system for their working viability.
ExpandrM High Fidelity PCR System (Boehringer Mannheim) was used for the PCR
reagents. The master mix was:












Each PCR reaction then contained 49 ¡rl of the above mixture plus 1 pl of factor VIII
cDNA, or 1 ¡rl HrO as non-DNA control. The reaction was performed in a DNA thermal
cycler (Perkin-Elmer Cetus and Perkin-Elmer), for 35 cycles with the thermal cycling
conditions as follows:
Initial denaturation: 95"C, 5 minutes
Denaturation: 95oC, 15 seconds
Annealing: 55oC, 30 seconds 35 cycles
Extension: 68oC, I minute
Final extension: 72"C, 7 minutes
Following PCR, the products were visualised by electrophoresis on a lo/o Agarose gel
using standard techniques and photographed using a Polaroid camera system.
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BRESAspinrM PCR Purihcation Kit (Bresatec) was used to puriry High Fidelity PCR
products, according to the manufacturing handbook.
3 .3 .I .2 Insertion, Transformation and Screening
BamH I (Pharmacia Biotech) was used to digest both the target gene (purified A1) and the
GST Gene Fusion Vector (pGEX-2TK, Pharmacia Biotech) at37"C. Ligation was then set
up on ice using T4 DNA Ligase (Biolabs) and left at 4"C overnight. The ligation products
were extracted the next day with phenol/chloroform. The pellet was finally washed in7}Yo
ethanol and dried in Speed Vac, before it was resuspended in 10 ¡rl sterile water.
The vector with A1 inserted was transferred into the E. Coli competent cell, DH5cr,
subjected to electroporation, and the cells incubated on LB-Amp (Luria-Bertani
Ampicilline) agar plates at 37"C overnight. Randomly selected colonies were removed
from the agar plates. Colony cracking was carried out by adding cracking solution (lysis
buffer plus loading buffer). Electrophoresis of each of these colony mixtures was used to
reveal the expected molecular weight of the vector plus A1 DNA (4.8+1.3 kb).
The colonies identified from the electrophoresis were then allowed to grow in a bigger LB-
A-p culture at 37oC overnight. After mini-preparation of the culture and
phenol/chloroform extraction, the vector DNA together with the inserted Al from the E.
Coli cells were purified, ready for the second round of gene insertion. BamH I digestion,
ligation, and transformation were performed again, using this biologically-obtained target
gene Al fragment, rather than the PCR product 41. Colonies selected by colony cracking
this time were then put into alatge culture for protein expression.
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3.3.1.3 Induction and Purification of the Proteins
IPTG was used to induce the expression of the GST fusion proteins. Cells were grown at
30oC, with 500 ¡rl of the culture taken out at the time points of 0h, 0.5h, th, 2h,3h, and 4h
after the addition of IPTG (0.1mM) into the culture. Samples were spun, pellets
resuspended in protein loading buffer, subjected to electrophoresis in IïYo acrylamide gel
and the gel stained with Coomassie blue. If the induction was successful, there should be
extra bands at the molecular weight of the A1 peptide (about 47 KD) seen in the lanes after
induction.
Purification of the targetprotein expressed by the E. Coli cells could be done by sonicating
the pellet spun down from the cell culture, and washing the supernatant in sepharose beads.
Purification \ryas also tried by running the supernatant from sonication through the resin
column with lysis buffer, and then washing the protein off with elution buffer.
3.3.2 l(estern blot with thrombin-clesvedfactor VIII fragment
3.3.2.1 Thrombin Cleavage and Protein Electrophoresis
Recombinat"rtu (50 IU/ml) or Baxter unformulated factor VIII (1400 IU/ml), and STA@-
ThrombinØ (3 NIH unit/ml) were used with the appropriate volumes so to keep the ratio of
the amount of factor Vlll:thrombin in the mixture about 100:1. Sterile water instead of
thrombin was used as a negative control, and the cleavage time was 15 minutes. At the end
of the reaction, ImmunoPure@ reducing buffer was added as a stop reagent as well as the
protein loading buffer.
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Proteins were heated at 95oC with loading buffer for 3-5 minutes, cooled to room
temperature and then loaded onto 7.5%o acrylamide gel. The amount of factor VIII loaded
in each lane was 1.5 IU. BenchMarkrM protein marker was loaded (10 ¡ll). The gel was
run at 20 mA in I X SDS-PAGE running buffer for 1.5 hours.
3.3.2.2 Transfer to Membrane
Following electrophoresis, the separating gel, a piece of nitrocellulose membrane of the
same size, together with four pieces of blotting paper were soaked in Semi-Dry transfer
buffer for approximately 10 minutes. Then assembled the gel-membrane sandwich in the
Hoefer Semi-Dry transfer apparatus according to the instruction on the lid, and the transfer
carried out at 0.8 mA/cm2 for 90 minutes. After the transfer, the membrane was blocked in
5% milk in PBS-0.1%oTween at 4"C for overnight.
3 .3 .2.3 Incubation with Antibodies
Primary antibodies, including monoclonal antibody MAS 530 (anti-heavy chain), MAS
531 (anti-light chain), and patient IgG were diluted 1/100 in dilution buffer (2.5% milk in
PBS-0.1%Tween). The membranes were cut into strips according to the design of the
experiment and each was incubated with a different primary antibody at room temperature
for two hours on a rocker. The membrane was washed once for l0 minutes, then 3 X 5
minutes with PB S-0. I o/oTween.
Secondary antibodies, including sheep anti-mouse and sheep anti-human IgG (Amersham)
were diluted 112000 and 1/1000 separately in antibody dilution buffer. The corresponding
secondary antibody was incubated with the membrane strip of the appropriate primary
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antibody for one hour at room temperature on a rocker. The wash steps were the same as
for the primary antibody, with an extra rinse with PBS at the end.
3.3.2.4 ECL Detection and Exposure to Film
The ECL reagents were mixed I :1 (1 ml of each) and placed in a glass plate. Excess buffer
was blotted off the membrane, which was then placed face-down onto the glass plate. It
was allowed one minute to incubate, while agitating gently. The membrane was then
removed from the solution and any excess blotted off, before being wrapped in a piece of
Glad-Wrap. The membrane was then placed into a cassette and films were developed after
exposure for eight minutes.
55
CHAPTER THREE
IN VITRO KINETICS OF FACTOR VIII INHIBITORS
1. Introduction
Circulating alloantibodies to factor VIII (factor VIII inhibitors) develop in patients with
haemophilia A, and inhibit factor VIII coagulant activity (Ware et al., 1992). The
development of inhibitors is particularly prevalent in patients with factor VIII <5o/o of
normal values (Kavanagh et a1.,1981; McMillan et a1.,1988). Factor VIII inhibitors also
arise spontaneously as autoantibodies in patients without hereditary deficiency of factor
VIII, causing the condition "acquired haemophilia" (Feinstain,1993; Mosher, 1996).
The kinetic behaviour by which inhibitors inactivate FVIII:C activity is one of the features
that has been occasionally used to characterise these inhibitors. Study of the kinetics of
factor VIII inhibitors may provide a better understanding of the mechanisms by which
inhibitors interfere with factor VIII:C activity. In addition, a knowledge of their kinetic
behaviour may lead to improvements in clinical strategies for treatment. Biggs et al. were
the f,rrst to describe the in vitro kinetic features of factor VIII inhibitors (Biggs et al.,
1972). Their study provided criteria for the classification of factor VIII inhibitors based on
kinetics, which have been widely accepted since the important publication in 1972.
Patients with severe inherited haemophilia tend to develop type I inhibitors, whereas
patients with acquired haemophilia develop type II inhibitors (Gilles et al., 1997; Hoyer
and ScandelLa,lg94; Pruthi and Nichols, 1999).
According to the description by Biggs et al., type I inhibitors exhibit second-order kinetics
while type II inhibitors follow more complex kinetics. They examined kinetic behaviour
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mainly by studying the time course of inactivation of factor VIII by factor VIII inhibitors.
They also examined the effect of varying the antibody concentration. Figure 3.1 shows
three examples of time course studies taken from Biggs et al. (1972 a). The logarithm of
the residual FVIII:C was plotted against the incubation time. There were two patterns
observed, as claimed by Biggs et al. which were characteristic for type I inhibitors: a linear
inactivation over two hour incubation (Figure 3.I a), or a two-phase curved line (Figure 3.1
b and c) ending with a stable residual FVIII:C level (or plateau) after two hour incubation
(Figure 3.1 c), depending on different antibody concentrations used. In contrast, Figure 3.2
shows the time course for a type II inhibitor (Biggs et al.,1972b). It was characterised by
causing a rapid initial loss of FVIII:C followed by a slow gradual decline (Biggs et al.,
re72b)
While the study by Biggs et al. (1972) introduced many concepts and evidence for the
kinetic features of the two types of factor VIII inhibitors, further descriptions of their
kinetic behaviour have since been minimal. This likely reflects diffrculties in applying the
concepts of Biggs et ql. to individual patient plasma samples. The problem is that the
methods used in Biggs study were complex and do not clearly lead to a definitive protocol
for the classification into the two types. This, for example, can be seen from the time
course results in Figure 3.1 and Figure 3.2. The time course curves of type I kinetics in
Figure 3.1 (c) show a pattern not distinguishable from the pattern in Figure 3.2 for type II
kinetics. Furthermore, in the examples given in Figure 3.1, a linear time course was seen
with one antibody 3.1 (a), and a curved time course was seen with the second antibody 3.1
(c). They both resulted in the same percentage of residual FVIII:C at the two hour
incubation point, suggesting that the antibodies in the two cases were present in similar
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FIGURE 3.1 Time Course Graphs for Type I Kinetics
(Reprint from Biggs et al. The mode of action of antibodies which destroy
factor VIII. I. Antibodies which have second-order concentration graphs. Br
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FIGURE 3.2 Time Course Graph for Type II kinetics
(Reprint from Biggs et al. The mode of action of antibodies which destroy
factor VIII. tt. Antibodies which give complex concentration graphs. Br J
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concentrations. Although Biggs et al. interpreted both of these as type I (second order)
kinetics, they in fact appear quite different.
In 1982, Gawryl and Hoyer expressed the findings of Biggs et al. (1972 a and b) in a
simplified form. They proposed that in an antibody concentration study, type I inhibitors
at high antibody concentrations caused complete inactivation of FVIII:C, whereas type II
inhibitors at the maximum concentration available were not able to completely inactivate
FVIII:C (Gawryl and Hoyer, 1982). This property reflects the second-order kinetics of
type I inhibitors and the more complex pattern of type II inhibitors.
Apart from these two major publications by Biggs et al. (1972 a and b), and Gawryl and
Hoyer (1982), only nine further publications have been found, and the details of
methodolo gy are scant in these publications. Papers which give some detail include five
using a study of time course (Allain and Frommel,l974; Bovill et a1.,1985; Gorden et al.,
1993; Gorden et al., 1994; Green et al., 1999), and one using a study of antibody
concentration (Peerlinck et a1.,1997). Nevertheless, it is not clear from these papers how
the methods adopted can provide true separation of the two types of factor VIII inhibitors.
For example, in Green et al.'s study, there was only marginal statistical significance
between the two types.
In addition, there are some publications that mention the kinetic classification of inhibitors
but do not state the method used (Michiels e/ al., 1997; Peerlinck et al.,1993; Santagostino
et al., 1995). Most of these publications were clinical case reports of only one to three
patients (Bovill et a1.,1985; Gorden et a1.,1993; Gorden et a1.,1994: Santagostino et al.,
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1995). In some studies there were larger numbers of patients: four cases (one type I and
three type II) in Michiels et a/.'s work (1997); 12 cases (all type I) in Allain and Frommel's
work (1974); and 14 cases (six type I and eight type II) in Green et al.'s work (1999).
From the above considerations, there are two main methods for determining the
classification of a factor VIII inhibitor: study of the time course and study of the effect of
varying the antibody concentration. An evaluation of the utility of these two different
methods is required so that the approach to this problem can be standardised. It is
therefore important to compare the application of both these methods to the same group of
patients. Such a study has not been previously published.
Further justification for such a study is that, since the work of Biggs et al. was published,
the methods to measure factor VIII:C have been automated and the one-stage assay has
replaced the two-stage assay as the most common method. Factor VIII inhibitors are now
generally measured in a system which quantitates their effect on FVIII:C in pooled normal
plasma, rather than in factor VIII concentrate. Therefore, it is pertinent to review the study
of in vitro kinetics of factor VIII inhibitors, with the aim of developing a standardised
approach to classify inhibitor types in patient samples, using currently available methods to
measure the effect of inhibitors on FVIII:C.
Therefore the aims of this study was to re-examine the previous methods used to classiff
the kinetic types of factor VIII inhibitors, and to develop a practical approach for a routine
laboratory to classiff inhibitor types based on in vitro kinetic behaviours. Specifically, the
arms were:
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TABLE 3.1 Clinical Data of 11 Haemophilia A Patients in the Kinetic Study
High responder: those have a strong anamnestic response to human factor VIII, and the inhibitor titre increases to >10 BU/ml; Low responder: those have a weak
response, and the inhibitor titre normally below 10 BU/ml.
A: AFIF (plasma derived factor VIII, high purity); P: porcine factor VIII; N: recombinant factor VIIa (Novoseven@); D: desmopressin; I: immunosuppression





















































































































































1) To study the time course of action of factor VIII inhibitors.
2) To study the relationship between the degree of inhibition and the concentrations of
inhibitors.
3) To determine the classification of the factor VIII inhibitors based on kinetics for a
number of patients, and to determine whether in this group of patients, there is a
relationship between the type of inhibitor and different clinical groups of patients (i.e.,
severe inherited, mild inherited and acquired)'
4) To determine if a relationship exists between the kinetic classification and the epitope
specificity of factor VIII inhibitors'
2. Methods
Eleven patients with haemophilia A and inhibitors, nine from South Australia (Royal
Adelaide Hospital) and two from Victoria (The Alfred Hospital), were studied. This group
comprised five patients with severe inherited haemophilia, three with mild inherited
haemophiliaandthree with acquired haemophilia (one male and two females). A summary
of the clinical and laboratory features of the 11 patients with haemophilia A used in this
study is shown in Table 3.1 . For two of the three acquired cases, there were no underlying
conditions found (Case 9 Si and Case 10 Bk), but they were elderly, which is a known risk
factor (Pruthi and NichoIs, 1999; Sallah, 1997). The third patient Mi (Case 11), was
postpartum when the inhibitor was found. The cases with inherited haemophilia had all
previously been treated with AHF (High Purity, CSL), which is the only human plasma-
derived factor VIII concentrate available in Australia. None had been treated with
reoombinant factor VIII. The samples studied were all obtained at least seven days after
the last infusion of factor VIII concentrate. Methods of plasma preparation and Bethesda
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assay to measure the inhibitor titre ìwere as described before in Chapter 2 (sections I.2 and
3.1.1). The inhibitor titre of the plasma samples used in the study ranged from 1.3 to 700
BU/ml. High-titre inhibitors (or high responders) were considered to be those with titres
greater than 10 BU/ml.
3. Results
3.1. Effect of Incubation Time
The time course of action of inhibitor plasma was studied during two to four hours in nine
patients. In these experiments a dilution of patient plasma was incubated with pooled
normal plasma as in the Bethesda method, and the residual FVIII:C level measured at time
intervals up to two to four hours. The dilution of plasma was chosen such that the residual
FVIII:C would be approximately 20-40% after two hours'
The results of two typical experiments (Case I and 9) are shown in Figure 3.3 and 3.4.
Residual FVIII:C (%) is shown plotted on both linear and logarithmic scales against the
incubation time. The pattern of the time course graphs appeared to be the same for eight of
the nine haemophilia patients studied. For each of them, there was a rapid initial decrease
in FVIII:C to near maximal inactivation at about 30 minutes incubation, followed by a
slight continuous decline. As expected, the degree of decrease in FVIII:C was greater at
higher antibody concentration, as displayed with Case 1 in Figure 3.3, but the pattern seen
with the two concentrations was similar. The majority of the graphs (eight of nine)
therefore resembled the results seen in the studies of Biggs et al . (Figttre 3 . I c). In Figure








































FIGURE 3.3 Effect of Incubation Time (Case 1, Du, BU:30)
A four hour incubation study was carried out using an equal volume of
inhibitor plasma and pooled normal plasma at 37"C. Residual FMII:C (%)
was measured at multiple time points and plotted on both logarithmic (a) and
linear (b) scales against the incubation time. Two dilutions of inhibitor










































FIGURE 3.4 Effect of Incubation Time (Case 9, Si, BU:140)
A two hour incubation study was carried out using an equal volume of
inhibitor plasma and pooled normal plasma at 37"C. Residual FVIII:C (%)
was measured at multiple time points and plotted on both logarithmic (a) and
linea¡ (b) scales against the incubation time. Three dilutions of inhibitor
plasma (7130, ll5} and 1/100) were chosen to give approximately 20Yo to




















FIGURE 3.5 Effect of Incubation Time (Case 11, Mi, BU:3)
A two hour incubation study was carried out using equal volume of inhibitor
plasma and pooled normal plasma at 37"C. Residual FVItr:C (%) was
measured at multiple time points and plotted on both logarithmic (a) and
linear (b) scales against the incubation time. Three dilutions of inhibitor
















over two hours. This is therefore the same as the pattern shown in the study by Biggs et al.
(Figure 3.1 a).
Biggs criteria were interpreted by Allain and Frommel (1974) as follows: Type I kinetics is
characterised by a plateau of residual FVIII:C occurring after a two hour incubation,
whereas type II shows a gradual decline following a rapid initial drop. 
'When our curves
were analysed using these criteria all the curves showed a rapid decline, but none showed a
convincing plateau. In all there is a slight further decline, even at four hours incubation.
Green et al. (1997) interpreted type I kinetics to be characterised by a linear decline
(second-order kinetics). However, in our data, only one (Case 11) appeared to be linear.
Because our patient population is diverse, containing patients with severe and mild
inherited haemophilia as well as acquired haemophilia, we would have expected to find
representatives of both type I and type II categories. Therefore, it seemed that in our
patients the study of the time course did not discriminate between type I and type II
kinetics. However, it was also possible that all the patients were of the same type,
presumably type I.
To further analyse this, it was questioned whether there may be differences in the slope of
the slow decline seen after the hrst phase that would allow a classification to be made. In
order to investigate such a possibility, nonlinear regression with the equation for two phase
exponential decay was performed using GraphPad Prism version 3.00 to fit the model to
the data. The equation is as follows:
y:Spanl .r-kl'x * Span2.r-kz'x I phteau
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The X value is the incubation time, and the Y value is the residual FVIII:C in percentage.
As defined in the program, phase 1 refers to the second (slow reaction) phase, while phase
2 refers to the first (fast reaction) phase. K, and Ç are the rate constants in the second
(slow) phase and first (fast) phase respectively. The greater the K, value, the steeper the
slope of the second inactivation phase. "Plateau" is the minimum residual FVIII:C (%) that
is automatically determined from the equation of the curve. "Spanl" is the distance
between the "Plateau" and the Y value at the inflextion point of the decay curve. "Span2"
is the distance between the inflextion point to the maximal Y value (I00yo, i.e., the Y value
when X value equals to zero).
The analysis showed that the decay curve for all patients was similar. V/ithout exception,
the model fitted well with each set of patient time course data. There was no significant
difference in the values of the relevant computer-generated parameters. In particular, the
K, values were not significantly different from each other, as shown by the overlapping
ranges for the 95o/o confidence intervals for Kr. Table 3.2 gives the time course results
analysed by the computer program. Case 11 (MÐ showed a residual FVIII:C (%) which
appeared to be linear rather than a curve by visual observation. The mathematical model
did not fit her data, as well as shown by a very wide confidence interval for Kr.
3.2. Antibody Concentration Study
3.2.1 Visual observøtìon of concentration grøphs
Experiments were carried out to ascertain the effects of varying the concentration of
inhibitors on the inactivation of factor VIII. A series of dilutions of plasma samples,
including full strength (FS) plasma, were incubated with pooled normal plasma for two
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TABLE 3.2 Comparison of Time Course Results from the Two Phase
Exponential Decay Model Analysis with the Kinetic
Classification by Antibody Concentration Study on 9 of 11
Patients
Time Course Study: Results generated by the computer analysis using GraphPad Prism
statistical program showing: ff as an indication of goodness of fit; The best-fit values for
Plateau (minimum residual FVIII:C%) and K, (rate constant of slow phase); The 95%
Confidence Interval of K,. There is no significant difference between the K' values for the
nine patient samples, and their 95o/o confidence intervals overlap with each other.
FIowever, all these patient samples were classified as to have either type I or type II
inhibitor by the later Antibody Concentration Study.
(4h): incubation duration for four hours instead of two.




1 . Du (1/10) 8 (4h) 0.9997 0.1628 0.017 0.010 to 0.023 I
Du (1/17) 8 (4h) 0.9992 0.2s12 0.008 -0.001 to 0.016
2 . Go (Ils) 8 (4h) 0.9992 0.0858 0.012 0.004 to 0.021 I
Go (1/8) 8 (4h) 0.9980 0.1026 0.005 -0.004 to 0.014
3.}]u(tl2) I (4h) 0.9996 0.0s 18 0.010 0.002 to 0.018 I
Hu (1/4) 8 (4h) 0.9986 0.1916 0.006 -0.004 to 0.015
4 .Fi (s16) 8 (4h) 0.9996 0.t217 0.019 0.01I to 0.028 I
Fi (3/s) 8 (4h) 0.9998 0.2t25 0.014 0.000 to 0.029
5 . Lo (FS) 6 0.9979 0.2382 0.012 -0.142 to 0.166 I
Lo (1/s) 6 0.9848 0.7llr 0.006 -0.345 to 0.356
6 . El(1/300) 6 1.0000 0.1599 0.023 0.023 to 0.023 il
El (1/5oo) 6 0.9993 0.3319 0.022 -0.1 10 to 0.1 5 5
7 . Bo (tll2) 6 1.0000 0.1343 0.017 -0.048 to 0.082 I
8.Ro I
e . si (1/30) 6 0.9997 0.1339 0.029 -0.131to 0.189 II
si (1/50) 6 r.0000 0.1444 0.014 0.001 to 0.028
si (1/100) 6 0.9999 0.2369 0.015 -0.019 to 0.049
10. Bk I
11 Mi (1/ro) 6 0.9867 0.5287 0.007 -735 to 735 il
hours, and the residual FVIII:C was measured. On a dilution curve graph, for plasma
samples with high-titre factor VIII inhibitor level (>10 BU/ml), residual FVIII:C plotted
against various antibody dilutions showed two different patterns on logarithm scale (Figure
3.6 and3.7). A steep slope and complete (>98%) FVIII:C inactivation at high antibody
concentrations was seen with two severe cases (Case I, BU:30 and Case 4, BU:13) and
one mild (Case 7,BU:23) case (Figure 3.6 and 3.7). This hts the definition of a type I
inhibitor as given by Gawryl and Hoyer (1982). A curvilinear pattern with a FVIII:C
plateau at high antibody concentrations was seen with one mild (Case 6, BU:700) and one
acquired (Case 9, BU:140) cases (Figure 3.6 and 3.7). This indicated incomplete
inactivation of FVIII:C even when antibody is in excess, and fits the definition of type II
(Gawryl and Hoyer, 1982). The residual FVIII:C at full strength plasma for Case 6 and
Case 9 were approximately 6%o and I2Yo respectively. Thus, the difference between the
two types of factor VIII inhibitors in their in vitro kinetic behaviour was clearly shown in
an antibody concentration graph, and this is consistent with the demonstration in Gawryl
and Hoyer's studies (Gawryl and Hoyer, 1982)
For the other six patient samples, it was not possible to characterise the concentration
response because of the low concentration of inhibitors. It seemed that it might be possible
to increase the titre of the inhibitor by concentrating it. One way to do this is to purify IgG
from plasma, and then subject it to a concentration procedure.
3. 2. 2 I g G p urìJïcøtio n fo r low-titre in hibitors
In plasma samples with inhibitor level less than 10 BU/ml, no clear classification could be
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FIGURE 3.6 Effect of Antibody Concentration
(Cases L-6)
A series of plasma dilutions for six cases were incubated for two
hours with pooled normal plasma. Residual FVItr:C (%) uas
plotted against antibody dilution, both on logarithmic scales. Case
1 and 2 were classified as having atype I inhibitor, while Case 6
was classified as having a type II inhibitor. Inhibitors from Case 3,
4 and 5 were unable to be definitely classified because of the low
titre.
The dashed line indicates 2Yo residual FVIII:C, which is the
minimum detectable residual FVIII:C in the experiment
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FIGIJRE 3.7 Effect of Antibody Concentration
(Cases 7-ll)
A series of plasma dilutions for six cases were incubated for two
hours with pooled normal plasma. Residual FVItr:C (%) was
plotted against antibody dilution, both on logarithmic scales.
Case 7 was classified as having a type I inhibitor, r,rhile Case 9
was classifîed as having a type tr inhibitor. Inhibitors from Case
8, l0 and 11 were unable to be definitely classified because of
the lowtitre.
The dashed line indicates 2Yo rcsidual FVIII:C, which is the
minimum detectable residual FMtr:C in the experiment
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IgG purification and concentration was performed with six plasma samples, including fow low-titre cases, one high-titre case (Bk) which could
not be def,rned by concentration study, and one normal donor sample.
*: Pooled fractions 7 ,8 and 9 eluted off sepharose-protein G column contained IgG'
**: Recovery calculated from the end of purification to the concentrated product.
t: Final inhibitor titre in IgG concentrate, with which the inhibitor type was defined.
N/A:Not available.
not a plateau could be achieved on the graph of concentration versus residual FVIII:C. To
try to solve the problem with these low-titre inhibitors, IgG was purified and concentrated
from patient plasma, and thus a higher inhibitor level was achieved for use in the antibody
dilution study. Table 3.3 shows the results of 13 individual experiments of IgG
purification and concentration on six plasma samples. Four of them were low-titre cases
(Case 3, 5, 8, and 11). One was a high-titre case (Case 10, BU:33) which could not be
defined by a concentration study using a plasma sample, and one was norrnal blood donor
sample. The yields during the concentration of purified IgG varied from experiment to
experiment, with the range of approximately 50Yo to 90Yo recovery in these 13 individual
experiments. The inhibitor titre in the concentrated IgG was found to be about 3-15 fold
higher than the original titre in plasma.
Three inhibitors: Case 3, Case 5 and Case 10, were successfully defined all as type I using
purified and concentrated IgG in this way. The classification of Case 8 and Case 1l
however, remained undetermined at the end of the study due to insuff,rcient plasma samples
available for IgG purification. Figure 3.8 (Case 3, 5 and 10) gives examples of kinetic
classification using purified and concentrated IgG in a study of the effect of antibody
concentration. Case 3 (Hu), who was a severe inherited case with baseline inhibitor titre of
4.8 BU/ml, was demonstrated to have a type I inhibitor by the antibody dilution curve,
after increasing the inhibitor titre to 42.5 BIJlml by IgG purification and concentration. In
another case of a patient with severe haemophilia (Case 5, Lo), the antibody concentration
curve also displayed a type I pattern, when the inhibitor titre was elevated from 1'2 BU/ml
to 11.3 BU/ml. In this patient the final titre was only obtained after six purification and
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FIGURE 3.8 Antibody Concentration Study Using
Purifred and Concentrated IgG
IgG purification and concentration were successful in three
cases (Case 3 Hu, Case 5 Lo, and Case 10 Bk) to obtain high
enough inhibitor titre. The antibody concentration study using
both plasma and IgG concentrate for these three cases was
plotted. All show a type I kinetic pattern, with a complete
inactir¡ation of FMII:C (residual FMII:C <2o/o, i.e., below the
dashed line).
1
different experiments. Case 10 (Bk) was a patient with acquired haemophilia A with a
high baseline inhibitor titre of 33 BU/ml. Although it appeared to be of the type I pattern
from the antibody concentration curve, there was still greater than 2% (3.6%) residual
FVIII:C when it was tested with full strength plasma. V/ith IgG purification and
concentration, an inhibitor titre of about 500 BU/ml was achieved. Complete inactivation
was achieved confirming that it is a type I inhibitor.
3.2.3 Møthematic analysis of the antibody concentratíon curves
The data from the antibody concentration studies was analysed with GraphPad Prism
nonlinear regression programs to find a model which would give a smooth curye through
the data points and find the best-fit values in the equation. The sigmoidal dose-response
(variable slope) model gave the best fit. The top value was set as the constant of 1.0
(100%) which fits with the experiment condition as the dilution curve theoretically starts
from the top point where the residual FVIII:C is 100%. The equation is as follows:
(Top - Bottom)
Y: Bottom -l
I + I 0 (LogECS)-X)'HillsloPe
When the Top value is set for the constant 1.0 (100%), the equation changes to:
(100% - Bottom)
Y = Bottom r
1+10 (LogEC 5 0-X)' Hillslope
The X value is the logarithm of the antibody dilution, and the Y value is the residual
FVIII:C in percentage. "Bottom" is Y value at the bottom plateau, and "LogEC5O" is the
antibody concentration required to compete for half the inactivation between "Bottom" and
"Top (1000á)". "Hillslope" is unitless, and denotes the slope of the curve. "Hillslope" is
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TABLE 3.4 Results of Antibody Concentration Study from the Sigmoidal Dose-Response (Variable Slope)
Model Analysis on 11 Patients
The results generated by the computer analysis using GraphPad Prism statistical program showing: P as an indication of goodness of
fit; The best-fit values for Bottom (where curve plateaus out), EC50 (antibody dilution to give 50%o inactivation), and Hillslope
(effectiveness of antibody); The 95%o Confidence Interval of Bottom as the possible objective measurement to distinguish type I
inhibitor (including zero) from type II (significantly positive from zero).








































































































negative in this study, which means the curve decreases as X increases. The Prism
program calculated the best-fit values of the variables Bottom Value, EC50, and Hillslope.
Table 3.4 shows the parameters obtained from the computer analysis
The overall goodness of fit of the data was satisfactory. The best-fit values for the model
given by the computer by analysing each set of data reflected that EC50 and Hillslope ,
which was the indication of the amount of antibody and the effectiveness of the antibody
respectively, do not have a tendency to form any recognisable subgroups with different
values corresponding to the different kinetic groups defined by later observation.
However, the result of the Bottom Value of the model showed a definite difference, which
divided the study population into two groups. For all the six type I inhibitors found with
previous non-mathematic methods (three cases through plasma study, three through IgG
study), the Bottom Value was always minus, with the 95o/o confidence interval of Bottom
Value including the zero point. In contrast, for the two defined type II inhibitors, the
Bottom Value was around l0% (one 6Yo and one 16%o), and the 95o/o conftdence interval
did not include zero.
This discovery was important, suggesting that the two types of factor VIII inhibitors could
possibly be objectively classified by deciding the parameters of the Bottom Value of the
sigmoidal dose-response (variable slope) model. To explore this observation, the antibody
dilution study data of the remaining three patients with low inhibitor titre and undefined
kinetic feature were analysed using the same model. The three patients were Case 4 (Fí,
severe inherited haemophilia with intron 22 inversion, BU:3), Case 8 (Ro, mild inherited
haemophilia, BU:2) and Case 11 (Mi, acquired haemophilia, BU:3). The result was
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Kinetic type of factor VIII inhibitors was defined basically through the study of effect of antibody concentration.
Inhibitors in patients 1,2, 6,7 , and 9 were defined type I or type II by both observation on plasma results and mathematic
analysis.
Inhibitors in patients 3, 5, and 10 were def,rned type I or type II by both observation on IgG results (*) and mathematic analysis.
Inhibitors in patients 4, 8, and 1I were deJined type I or type II by mathemøtic analysß alone.
del.: deletion; inv.: inversion; N/A: not avaílable; *: result obtained with IgG instead of plasma.
encouraging. For Case 11, the only acquired patient among the three, apositive Bottom
Value of 22Yo and the conf,rdence interval of 16-280/o were seen, which was a typical
mathematical feature for the type II. This result was clearly different from the results of
Case 4 and Case 8, in which the typical type I pattern was shown as a minus Bottom Value
and a confidence interval including zero. The results of the classification by this
mathematical analysis strengthen the confidence in the judgement of the type from visual
observation of the curves. A summary of the kinetic classification of factor VIII inhibitors
in 1 1 patients based on in vitro antibody concentration study was shown in Table 3.5.
3.3 Effect of Extrø Source of Factor VIII
The aim of this section was to determine whether further inhibitor activity can be detected
in incubations that have reached their maximum degree of inhibition of FVIII:C, i.e., after
equilibrium is reached. This is pertinent to the study of type II inhibitors which are
characterised by incomplete inactivation of FVIII:C after their incubation with normal
plasma, even when very high concentrations of inhibitor are present. The study of Biggs e/
al. (1972 b) briefly described data for one patient with acquired haemophilia, where it was
shown that addition of more factor VIII during the slow phase of factor VIII destruction
was followed by rapid destruction of the newly added factor VIIL
In these experiments AHF was used as the source of factor VIII, as described in Chapter 2,
section 3.1.5. The initial starting concentration of factor VIII in the incubation mixture
with patient samples was 1.0 IU/ml. After four hours incubation, and based on the assay
result at that time, a small volume (approximately 10-20 pl) of AHF was added in an
amount calculated to adjust the factor VIII:C in the incubation mixture back to 1.0 IU/ml.
68
The results in Figure 3.9 show two different patterns, one typical of type I (Case l)
inhibitor, the other typical of type II (Case 9) inhibitor
In Case I (BU:30), after the addition of an extra amount of AHF at the end of four hour
incubation, there was no obvious inactivation of additional FVIII:C over the subsequent
four hours. Case 9 (BU:140), which was a type II inhibitor case, however, gave a
significant further inactivation of the extra FVIII:C (in plasma dilution 1/50). Both chosen
dilutions of the two plasma samples brought the residual factor VIII:C in each mixture to a
similar level after four hours incubation. This observation could be summarised as type I
inhibitor can not neutralise additional FVIII:C after equilibrium is reached, while type II
inhibitor can (Biggs et al., 1972; Bovill et al., 1985). In this study, the results were
consistent with the classification result of these two cases by antibody concentration
studies as described above.
However, misleading results were seen when different dilutions of plasma samples were
used. As shown in Figure 3.10 (a), the same type I inhibitor (Case 1) gave a false "further
inactivation" of extra FVIII:C when it was too much in excess of antigen in the incubation
mixture. In this experiment, three different dilutions (ll4,116, and 1il0) of plasma of Case
1 were tested. With the dilutions of Il4 and 116, a further inactivation of additional
FVIII:C was observed, due to the excess amount of antibody in the reaction mixture. The
result with dilution 1/10 remained the same as the previous experiment, showing no further
inactivation, as characterised for type I kinetics.
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FIGURE 3.9 Study of Effect of Extra Source of X'actor VIII
Patient plasma samples (Case l, lll0 dilution and Case 9, ll50 dilution) were incubated
with pooled normal plasma for an extended time course study. For the control, commercial
factor VIII dehcient plasma (Organon, Teknita) was used instead of inhibitor plasma.
After four hours incubation, an extra amount of AHF was added, and the reaction mixture
was incubated for another four hours. Remaining FVIII:C (IU/ml) was measured at
different time points, and plotted against incubation time, both on linear scales.




































































FIGURE 3.10 Further Study of Effect of Extra Factor VIII
Case 1 (a) and Case 9 (b) were studied in more plasma dilutions. The methods
were the same as described before for Figure 3.9. After four hours incubation,
an extra amount of AHF was added, aiming to bring the FVItr:C level in the
reac"tion mixture back to 1.0 IU/ml. Remaining FVIII:C (IU/ml) was measured
during the time course. *: reaction mixture with the extra source of factor VItr.
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Similarly, for a type II inhibitor (Case 9), when the antibody concentration was too low, no
inactivation of the added factor VIII was observed. As shown in Figure 3.10 (b), the
plasma of Case 9 were tested with three dilutions: ll5,Il50, and 1/100. V/ith the dilutions
ll5 and 1150, it showed a further neutralisation of extra factor VIII, consistent with the
previous result. But with the dilution of l/100, there was no obvious inactivation of
additional factor VIII, as the antibody amount was not sufficient to show such a change in
a gross level. Therefore the results of this method are dependent on the selection of a
critical level of inhibitor for the incubation mixture. This renders the method impractical
for routine application to distinguish type I and type II inhibitors.
3.4 Effect of Initiøl Factor VIII Concentrøtion
The aim of this section was to determine the effect on kinetics of reducing the initial factor
VIII level in the incubation mixture. A reduction in the initial factor VIII concentration
will alter the ratio of antibody:antigen, and should provide antibody in excess of antigen.
We considered that this may increase the sensitivity to the effect of inhibitors, and facilitate
the demonstration of different kinetics for type I and type II. However, Biggs et al. (1972
b) was not successful in demonstrating that kinetic behaviour could depend on initial factor
VIII level.
The study of the initial factor VIII concentration in the reaction mixture, was carried out
with two severe inherited (Cases 1 and 5) and two acquired (Cases 9 and 1l) patient
samples. Each inhibitor plasma was tested at four different dilutions, and each of these
dilutions was tested against four dilutions of pooled normal plasma. The four dilutions of
normal plasma therefore provided four different initial factor VIII concentrations. Residual
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FVIII:C in the mixture was measured after two hours. Figure 3.11 shows the result of the
four cases studied, with the initial factor VIII (IU/ml) plotted on X axis, and the residual
FVIII:C (%) on Y axis. The four different concentrations of initial factor VIII tested were
full strength,2:3, l:2, and 1:4 dilutions of routine pooled normal plasma. As observed
from Figure 3.1 1, regardless of the initial factor VIII concentration, for a given dilution of
a patient plasma, there was always a fixed percentage of FVIII:C destroyed within a two
hour incubation. For each of the four patients, we studied four different antibody dilutions,
which covered a reasonable range of inhibitor strength. The degree of the inhibition was
proportioned to the strength of the antibodies. There was as expected, a decrease in the
residual FVIII:C correspondent to an increase in the antibody level.
Figure 3.12 (Case 1) shows the results when the residual FVIII:C (%) is plotted against the
antibody dilution, instead of the initial factor VIII concentration on X axis. It is clearly
seen from the graph that the four dilution curves with different initial factor VIII level are
overlapping each other. This again reflects that the adjustment of the initial factor VIII
level does not have a significant effect on the residual factor VIII:C (%). The results from
the other three cases studied show the same pattern plotted in this way. Therefore,
decreasing the initial factor VIII level did not increase the sensitivity for detection of the
inhibitors.
4. Chapter I)iscussion
Biggs et al. (1972 a and b) and Gawryl and Hoyer (1982) mainly used study of time course
and antibody concentration to examine the two different types of kinetics of factor VIII
inhibitors. The validity of those methods has not been studied in detail. In addition, no
7l
F'IGURE 3.11 Study of Effect of Initiat Factor VIil Concentration
(four cases)
For each case, four different patient plasma dilutions were incubated for two hours with an
equal volume of four different concentrations of initiat factor VIII, i.e., full strength,2:3,
l:2 and 1:4 dilutions of routine pooled normal plasma. The residual FVIII:C (%) is plotted

















Case 11 (BU=3, Type I)





















































































FIGURE 3.12 Study of Effect of Initial Factor VIII
Concentration (Case 1)
Plasma sample from Case I was tested with four antibody dilutions: 1/100,
7150, ll20 and l/10. Each antibody dilution was incubated with four
different dilutions of pooled normal plasma (full strength, 213, ll2 and ll4),
in order to obtain different initial factor MII level. The residual FVIII:C (%)
after two hours was plotted against antibody dilutions, both on log scales.
The four curves observed were overlapping with each other, even though the
initial FVItr:C level in each was different.
FS:full strength. PN:pooled normal (plasma).
one has published a study of a group of patients by both these methods. In this project, in
order to examine the in vitro kinetics of inactivation of factor VIII by factor VIII inhibitors,
the effects of incubation time, antibody concentration, the addition of extra factor VIII and
varying the initial factor VIII level were studied in the patient group of 11 haemophilia A
cases. These methods are different ways to explore the behaviours of the inhibitors in their
interaction with FVIII:C. In the studies of the effect of incubation time, there was no
signif,rcant differences in the patterns of inactivation among the nine patient samples
studied, both by visual observation of the time course curve and the mathematical analysis
of the experimental data. This suggested that, with the experimental methods used here,
the study of effect of incubation time will not be helpful to distinguish the kinetic features
of the two types of factor VIII inhibitors. Only one approach, the effect of antibody
concentration , was useful to classiff inhibitors as type I and type II. Table 3.2 shows the
comparison of the analysis of time course results generated by mathematical analysis, with
the final classification results determined by the antibody concentration study.
The results showed that the most promising way to differentiate two types of factor VIII
inhibitors based on their in vitro kinetic behaviour is the antibody dilution study, in which
two distinctive patterns of FVIII:C inactivation can be seen when sufficiently high amounts
of antibody are present. This study was consistent with previous studies (Gawryl and
Hoyer, 1982) as it demonstrated that type I inhibitor completely neutralises all available
FVIII:C (>95%) at high antibody concentrations. Also the type II inhibitors in this study
have more complex kinetics and cannot neutralise all available FVIII:C even when tested
undiluted, so a curvilinear pattern with a plateau at high antibody concentration is typical.
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Three inherited haemophilia A patients (two severe, one mild) were classified as having
type I inhibitors, and two (one mild inherited case and one acquired case) as having type II
inhibitors, by studying the effect of antibody concentration using patient plasma.
Generally, samples with >10 BU/ml inhibitor could be classified on the basis of an
antibody dilution study using plasma. Nevertheless, one patient was an exception and
although the plasma contained more than 10 BUiml inhibitor titre, it still could not be
defined by the dilution study with plasma (Case 10 in this study). Three more type I
inhibitors (two severe cases and one acquired case) were defined later using purified,
concentrated IgG to study the effect of antibody concentration. V/ith the GraphPad Prism
statistical program, the three remaining undetermined samples were classified using
extrapolation of the concentration curve. In our small patient population, both types I and
II were found in the mild/acquired group. This study is therefore consistent with the
general concept that factor VIII inhibitors that develop in severe haemophilia A patients are
usually type I, and those whose inhibitors form in mild haemophilia cases may be either
type I or type II (Gilles et a\.,1997; Hoyer and Scandella,lgg4; Pruthi and Nichols, 1999).
In the acquired haemophilia inhibitor patient group (n:3), one was determined to be type I
and the others were type II. Although it is possible that type I inhibitors may be more
prevalent among acquired haemophilia than previously realised, this should be clarified in
alarger study.
Use of the mathematical formula for a sigmoidal dose response curve to calculate the
Bottom Value of the curve has provided useful data for classifying the kinetic properties of
the two types of factor VIII inhibitors. All cases of type I inhibitors gave a negative
Bottom Value. However, the 95o/o confidence interval for that value included zero,
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indicating that it did not differ significantly from zero. In contrast the concentration curves
for type II cases were characterised by having both a Bottom Value and its 95olo conhdence
interval significantly above zero. This criteria led to a classification consistent with the
result obtained by using observation of the antibody concentration curves of those
inhibitors which were high titre. For inhibitors which were low-titre, again, this
mathematical formula gave the same classification as the result gained from an antibody
dilution study using purified and concentrated inhibitor IgG. In addition, for the three
cases in this study (Cases 4, 8 and 11) whose inhibitor type had remained unidentified
because it was not possible to obtain the antibody in high titre, this formula was also able
to classify their kinetic type as well. This was achieved by examining the best fit Bottom
Value and the 95Yo confidence interval of the value generated by the computer program.
The mathematically calculated result for a type I inhibitor, showing that the bottom of the
curve tends towards zero, is in keeping with the complete inactivation of FVIII:C observed
visually on the antibody concentration curve. A positive Bottom Value shown by a type II
inhibitor, is in keeping with its inability to completely neutralise factor VIII even when at
high antibody concentrations. This suggests that the use of a mathematic formula to
classiff factor VIII inhibitors based on antibody concentration studies, is a useful and
objective method of analysis. This mathematical method is therefore, a reasonably
convincing and objective way to distinguish the two types of factor VIII inhibitors. It is
important however, to mention that the mathematical formula is an extrapolation of the
curve based on the limited data which was obtained from plasma. Therefore, interpretation
by this mathematical analysis should be cautious if the number of data points is not
sufficient. The application of this method in a larger number of patients is still required in
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order to conflrm the reliability of this method. This may be difficult to achieve due to the
relatively low number of inhibitor patients in the population. Nevertheless, from our point
of view, the goodness of the fit of the data and the reasonable classification result for each
of the 1 1 patients in this study, have given sound supportive information to the evaluation
of this mathematical analysis
We concluded that, in order to classiff the kinetic type of factor VIII inhibitors, the use of
an antibody concentration study is an effrcient and readily standardised method for those
high-titre inhibitors. To solve the problem of those low-titre inhibitors, which are
becoming more common due to improved management of the patients (Lloyd et a1.,1997),
the approach of using purified and concentrated IgG to examine the effect of antibody
concentration is useful. The use of mathematical formula analysis, can also be considered
as apart of the assessment of the result. Table 3.5 summarises the final classification for
our patients, achieved using the antibody concentration studies.
Type II inhibitors do not completely inactivate all available FVIII:C, even when tested
undiluted. This kinetic property is consistent with the in vivo finding that in some patients,
there is always detectable FVIII:C level, even though there is also a signihcant inhibitor
titre (Rizza and Biggs, l9l3). The reasons behind such differences in neutralisation of
FVIII:C by the two types of inhibitors is not elucidated.
There are two possible hypotheses to account for these differences. One is that, type I
inhibitors have high binding affinity for the factor VIII molecule, while type II inhibitors
have relatively low affinity binding (Allain and Frommel,1974; Gilles et al.,1997; Hoyer
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and Gawryl, 1984; Kasper, 1984). This hypothesis explains well the effect on an extra
amount of factor VIII added during the time course experiments (Figure 3.9). Because
type II inhibitors bind loosely to factor VIII, it is possible for them to dissociate from the
original factor VIII molecules, and bind to the factor VIII molecules which also become
inactivated. This hypothesis would imply that there is a permanent inactivation of FVIII:C
by the type II antibodies. Hence the original factor VIII remains inactivated after it has
dissociated from the antibody. An alternative explanation for the type II kinetics is that,
those bound antibodies can remain bound but still inactivate further factor VIII. This
seems inherently unlikely. However, there is no direct experimental evidences to verifr
either possibility.
Of interest is the plateau which is found in patients with type II inhibitors in the antibody
concentration studies. A possible explanation for this is that type II antibodies might only
partially inhibit function. This could for instance occur if they blocked only part of an
important functional site. For instance it is likely that phospholipid binds to multiple sites
in the C2 domain. An inhibitor directed at only some of these sites would likely not
produce a complete inhibition. Nevertheless, the finding by Gawryl and Hoyer (1982) that
removal on protein-A-sepharose of antigen-antibody complex did not reduce factor VIII
activity in the mixture, argues against this hypothesis. In future studies, it would be
interesting to explore this hypothesis further, perhaps by repeating the experiments by
Gawryl and Hoyer.
It is possible that in some patients there may be a mixture of both type I and type II
inhibitors. In support of this, some researchers have demonstrated that human polyclonal
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antibodies behaving as type I inhibitors could be converted to type II after neutralisation of
the type I inhibitors in the mixture by addition of anti-idiotypic antibodies (Gilles et al.,
teeT).
In our experiments, type I and type II inhibitors could not be distinguished from the results
of the time course study. This is quite different from Biggs' conclusion. Nevertheless, in
re-examining our data and reviewing Biggs' paper, it seems likely that she would have only
observed arapid initial linear decline (Figure 3.1 a) when the antibody was in excess of
antigen. The difficulty with this concept from a practical point of view was that it is
diffrcult to define when antigen or antibody is in excess. In our time course experiments,
the percentage residual FVIII:C measured after two or four hours incubation were similar
to those seen by Biggs, suggesting a similar ratio of antigen to antibody. For each
individual patient sample, at least two antibody concentrations were selected for the
experiment, in order to ensure a reasonable and consistent range of the ratio of
antibody:antigen in the reaction mixture. Therefore, it seems unlikely that our failure to
detect a linear pattern was due to our choice in inhibitor concentration.
The results of effect of incubation time in this study not only disagree with Biggs' criteria,
but are also diffrcult to interpret in the light of the results of the two other main studies.
Among the few papers with detailed experiments carried out to study the kinetics of factor
VIII inhibitors in a small patient group, Allain and Frommel (1974), and Green et al.
(1999) claimed to show a typical pattern for type I inhibitor in a time course studies.
However in Green's study the difference claimed between type I and type II were based on
only marginal difference in statistical f,rt between a straight line and an exponential curve.
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In Allain's study the differences between the two types depends on a value judgement
relating to the steepness of the slope of the supposed plateau phase. Neither of the
concepts in these two studies can be applied to our findings
In our study the time course experiments did not differentiate the inhibitors into two types.
This is in contrast to the very definite classification achieved in our studies of the effect of
antibody concentration. The reason for the failure of the time course experiments to
demonstrate any difference between the subjects may partially be that our experiments
were carried out under different conditions compared to the methods used by Biggs et al.
(1972, a and b), Allain and Frommel (I974), and Green et al. (1999). For instance, pooled
normal plasma was used instead of human intermediate-purity factor VIII as a factor VIII
source in our test, which may cause different antigenic exposure and antigen-antibody
binding characters. Another important hypothesis could be that, the inhibitor patients in
this study were different from those in the other studies. AHF (High Purity, CSL) is used
as the only plasma-derived factor VIII concentrate in Australia, and this concentrate may
differ antigenically from factor VIII used in other patient groups around the world.
The results of our study showing no relationship between the classification by time course
and the classification by concentration effect shows for the first time that there are
weaknesses in previous concepts of classification. A robust classification scheme would
produce a consistent classification in all groups of patients. So far there is no explanation
with supportive experimental evidence to clarify the causative reasons for the different
results between our study and the previous publications. Re-examination of the previous
methods used to classify inhibitors did show difficulties in comprehension, execution and
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interpretation of the results. However, our study is the first, from the practical point of
view, to carry out a systematic study of in vitro kinetics of factor VIII inhibitors to classifu
inhibitor types in a small but diverse group of patients with haemophilia A. A successful
approach for a routine and research coagulation laboratory to classiff factor VIII inhibitors
based on in vitro kinetics has been established, based on the antibody concentration study
Some of the other possible kinetic features of the factor VIII inhibitors were also explored
in this study, with some alternative experiments carried out in attempt to classiSr low-titre
inhibitors. One method is to examine the effect of extra source of factor VIII. Biggs et al.
(1972 b) once described a type II inhibitor showing a rapid destruction of the newly added
factor VIII during the slow phase of the reaction. However, in the same publication work,
they claimed contradictorily that, in both reaction mixtures involving type I and type II
inhibitors, most of the antibody activity had been neutralised by the first addition of factor
Vil. Thus there was no significant destruction of added FVIII:C by either type of these
inhibitors, as demonstrated by one of their experiments (Biggs et al.,1972b).
Also, in a case study of a type II inhibitor in a mild haemophilia patient in 1985, the effect
of adding an extra source of factor VIII after reaching the reaction equilibrium was studied
(Bovill et al., 1985). The addition of factor VIII concentrate to the reaction mixture after
four hours incubation led to a significant further neutralisation of FVIII:C over the
subsequent four hours. This was explained to be due to the incomplete inactivation of
FVIII:C by type II inhibitor in the first four hours incubation, which is consistent with the
clinical picture of incomplete inactivation of FVIII:C following large dose of factor VIII
concentrate administration in this patient (Bovill et a|.,1985).
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In our extended time course study to examine the effect of an extra source of factor VIII, a
type II inhibitor did neutralise additional FVIII:C after equilibrium was reached, while a
type I inhibitor can not. This is consistent with the concepts that type II antibodies are only
loosely botmd with antigen. But the experimental conditions required to demonstrate such
kinetic difference are so critical that the interpretation of results is not straight forward. In
most situations, if the amount of antibody and factor VIII does not satisfr the certain ratio,
i.e., too much antibody in a type I mixture, or too much antigen in a type II mixture, the
experiment will give misleading results
Another way to examine the kinetic features of the two types of factor VIII inhibitors is the
study of initial factor VIII concentration. As a strategy alternative to purification and
concentration of the antibody, we explored the use of a lower initial factor VIII
concentration to increase sensitivity. In our studies, a fixed percentage of FVIII:C
destroyed within two hour incubation was always seen with a given patient plasma
dilution, no matter what the initial factor VIII concentration was, and what the type of
inhibitor was. This was disappointing because we had expected that at lower initial factor
VIII level, there would be a steeper decline with increasing antibody concentration.
5. Chapter Summary
In this in vitro kinetic study of factor VIII inhibitors, a variety of methods were used to
characterise the kinetic features of the factor VIII inhibitors from 11 haemophilia A
patients, including five severe, three mild and three acquired cases. By re-examining the
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previous described methods and exploring possible new alternatives, an approach to
classify factor VIII inhibitors based on their in vitro kinetics has been established.
o Type I and type II factor VIII inhibitors can be distinguished by antibody concentration
studies. This requires a relatively high level of inhibitor (>10 BU/ml). Purified and
concentrated IgG concentrate is helpful for those weaker antibodies. On an antibody
concentration curve, type I inhibitor is characterised by a steep slope and complete (>
98%) inactivation of FVIII:C at higher antibody concentrations, while type II inhibitor
gives a plateau and incomplete inactivation even at higher antibody concentrations.
. The use of a mathematical program (GraphPad Prism) to analyse the dilution curve data
with the sigmoidal dose-response (variable slope) model is useful to objectively
distinguish the two types of inhibitors. The 95Yo confidence interval of the Bottom
Value of the equation can be used as a criteria for discrimination: there is a zero for type
I and a positive result for type II.
. Eight type I inhibitors were found with five severe cases, two mild cases, and one
acquired case, using a combination of both observation and mathematical methods. At
the same time, three type II inhibitors were found with two mild cases and one acquired
case.
o Using the Bethesda method as the basis of experiments, other alternative ways,
including the time course study, study of effect of extra factor VIII, study of initial
factor VIII level etc., were not successful for classification of factor VIII inhibitors.
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CHAPTER FOUR
ELISA METHOD TO DETECT FACTOR VIII ANTIBODIES
l.Introduction
The term "inhibitor" is used for antibodies detected with functional assays such as the
Bethesda and New Oxford assays (Mondorf et al., 1994). These methods measure the
ability of those antibodies to bind functional epitopes involved in coagulant activity. It is
not known whether, or to what extent, post-transfusion antibodies may also arise against
epitopes which are not essential for function. However, there is evidence of the existence
of antibodies capable of binding to factor VIII, but devoid of neutralising activity (Gautier
et al.,1996; Mondorf et al., 1994). In these studies, immunoassays such as ELISA were
used to detect factor VIII antibodies
Theoretically, immunoassays that are based on the interaction between immunoglobulins
and the antigenic sites on factor VIII molecules are able to detect both inhibitory and non-
inhibitory antibodies. ELISA is one type of immunoassays that have been developed to
detect the binding of factor VIII antibody to factor VIII. The results of ELISA showed a
good correlation with the Bethesda assay in a report of a study on 18 patients with
haemophilia and five normal subjects (Regnault and Stolz, 1994). In contrast, another
study showed that in a group of patients with inherited haemophilia A, 36% (8 otÍ of 22)
had a positive ELISA result, but all were without a positive Bethesda titre (Dazzi et al.,
1996). Furthermore, using the method of ELISA in severe haemophilia A patients with
intron 22 inversion, the same group reported a high prevalence (ïlyo, 13 out of 16) of anti-
factor VIII antibodies (Vianello et al., t997). 'When the Bethesda assay was used, only
25Yo of these patients were found to have inhibitors.
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The clinical impact of such non-inhibitory antibodies has yet not been fully elucidated.
However, it is possible that they could bind to factor VIII and cause it to have a reduced
half-life in the circulation. The assessment of anti-factor VIII antibodies solely by a
functional assay such as the Bethesda assay may not be adequate for the complete
evaluation of the overall antibody response. It was therefore important to determine in our
patients whether antibodies to non functional sites on the factor VIII molecule could be
detected. We studied a group of patients with haemophilia by both an ELISA assay and
the Bethesda assay. The aim was to determine whether there was a relationship between
the results of these two assays. A positive titre by ELISA in a patient who was negative by
the Bethesda method would be evidence for an antibody against a non-functional epitope.
The specific aims were:
1) To set up an ELISA method suitable for a routine or research coagulation laboratory to
detect factor VIII antibodies, using commercial recombinant factor VIII product.
2) To investigate a number of haemophilia A patients, including a group of patients with
intron 22 gene inversion, using the ELISA method. Compare the results with those
obtained from the Bethesda assay, in order to determine if there is a correlation between
the two methods in terms of detecting factor VIII antibodies.
3) In a group of severe haemophilia patients, to compare the ELISA inhibitor results for
patients with the intron 22 gene inversion to the results for patients without the inversion.
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2. Methods
2.1 Estøblìshment of ELISA to DetecÍ Føctor VIII Antibody
The ELISA method is described in Chapter 2, Section 3.2. To set up the method, a few
experimental conditions were tested and then optimised, including the concentration of
factor VIII to coat the plates and the buffer system. Recombinant factor VIII
(RecombinaterM, CSL) (stock concentration 50 IU/ml) was diluted in different final
concentrations (1 IU/ml, 5 IU/ml and 10 IU/m) in both carbonate buffer and PBS buffer,
and was used to coat the microtitre plates. Monoclonal anti-factor VIII antibody ESH 8
(American Diagnostica Inc.), which is directed to the C2 domain of the light chain (aa
2248-2285) (stock inhibitor titre >5,000 BU/ml), was used as the primary antibody to bind
to factor VIIL A number of normal plasmas were also studied as negative controls
Primary antibodies were studied in a series of dilutions: seven dilutions for ESH 8 (from
1/500 to 1132,000), and six dilutions for human plasma (IlI0, U50, U100, 11200, 1i500
and l/1,000)
Coating plates with RecombinaterM 5 IU/ml in carbonate buffer was the minimum factor
VIII concentration to give a good linear relationship between monoclonal antibody dilution
and OD reading. Also this level of factor VIII for coating gave acceptably low OD values
in a buffer blank and normal control plasma. Therefore it was used as the coating
concentration in all subsequent tests in this study. The standard series of dilutions used for
primary antibody þatient plasma) were 1/10, 1150, 1/100, 11200, 1/500 and 1/1,000.
However, the OD reading of 1/100 antibody dilution was chosen to summarise the data.
Thus unless specified, all the results in this study were referred to as the results gained with
l/100 plasma dilution.
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Twenty normal plasma samples were studied to establish the normal range of OD reading
for the ELISA method. The cut-off value was defined as the mean value of the OD
readings of the 20 normal controls plus 3 SD. Any OD reading which was equal to or
greater than the cut-off value \¡r'as considered as a positive ELISA result
2.2 Patient Group
A total of 50 haemophilia A patients (33 severe, 5 moderate, 6 mild and 6 acquired cases)
were studied by both the ELISA method and the Bethesda assay. Among the adult
patients, 10 (including 5 severe) were from Royal Adelaide Hospital Haemophilia Centre,
and 12 (including 9 severe) from the Haemophilia Centre of the Alfred Hospital in
Victoria. Twenty-four patients showed a detectable inhibitor by Bethesda titre and26 were
undetectable. A summary of the patient data in this study was shown as Table 4.1. The
inhibitor titre where positive ranged from I to 700 BU/ml by the Bethesda assay. Among
the severe cases (n:33), we studied 20 with and l3 without the intron 22 gene inversion.
2.3 Different Føctor VIII Products
In addition to RecombinaterM, plasma derived factor VIII AHF (High Purity) (CSL,
Australia) and unformulated recombinant factor VIII generously provided by Baxter were
also used to coat the micrometre plates, in order to obtain more information about this
method.
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TABLE 4.1 Summary of 50 Haemophilia A Patients in the ELISA Study
to Detect Factor VIII Antibodies
Severe, Moderate, and Mild: all refer to inherited patients.
N/K: (gene mutation) not known according to current investigations.
NiD: (inhibitor titre) not detectable by the Bethesda assay.
OD Reading: OD reading of 1/100 plasma dilution.
ELISA Result *l-t " 
,+" 
defined as OD reading : or > cut-off value (0.29);






























































































































































































































3.1 The Normal Range
The normal range for the ELISA method was determined by testing 20 normal subjects
The mean OD value for the 1/100 plasma dilution was 0.19, with minimum 0.13 and
maximum 0.26. The SD was 0.04, and the 95Yo confidence interval of the mean was 0.17
to 0.20. A cut-off value for positivity was calculated as the mean value plus 3 SD, which
was 0.29. A positive ELISA result was defined as a result with OD reading equal to or
greater than 0.29; a negative ELISA result was less than 0.29. Figure 4.1 shows the
binding curve for two normal controls and two patient samples, with respectively negative
and positive ELISA results.
3.2 Comparison of Results Between ELISA and Bethesda Assay
A group of patients with haemophilia A were tested using the ELISA method. Fifty
patients were studied,24 with inhibitor titres ranging from I to 700 BU/ml, and26 without
detectable inhibitors by the Bethesda assay. Figure 4.2 and Table 4.2 summarise the
comparison of the results obtained from the two assays. Figure 4.2 shows that all the
patients who were negative by the Bethesda assay (n:26) were also negative by ELISA.
Therefore there was no evidence for antibodies which bound to factor VIII but did not
cause a functional defect. In Table 4.2 more detail is shown for the individual patient
groups. Once again, there is a strong correlation between the two assays. Of 24 who were
positive by the Bethesda assay, only one was negative by ELISA. The sensitivity of the









FIGURE 4.1 ELISA Binding Curves for Two Patients
and Two Normal Controls
Both patient and normal plasma samples were tested at six dilutions: 1/10,
1/50, l/100,11200,1/500 and 1/1000. OD readings at 11700 dilution were
later on chosen to summarise the ELISA results. The two patient samples
in this diagram were considered to have a positive ELISA result, while the


















































FIGURE 4.2 ELISA Results in Patient Groups with or
without Bethesda Titre
Twenty normal controls were used to determine the positive cut-off for
the ELISA (mean+3 SD). Fifty haemophilia A patients were tested,
including 18 inherited cases with antibodies detected by Bethesda
assay, 26 inherited cases negative by Bethesda assay, and 6 acquired
cases. For those cases with a positive Bethesda titre, all acquired and
most inherited were also positive by ELISA. For those without
detectable antibodies by Bethesda assay, none had a positive ELISA
result.







Table 4.2 Comparison of ELISA and Bethesda Results in I)etection
of Factor VIII Antibodies in 50 Haemophilia A Patients
BU (+¡ BU G)































Total 24 26 50
Prevalence of positive ELISA result in patient groups +/- BU:
Patients with BU (+): n:24
ELISA (+): 23124:96Yo
Patients with BU (-): n:26
ELISA (+): 0126:0o/o
Sev, Mod, and Mil: inherited haemophilia A patients with severe, moderate or mild
clinical status.
Acq: patients with acquired haemophilia A
Figure 4.3 shows the corelation (R2:0.72; P:0.0001) between the Bethesda titre and the
OD reading on 24 patients with a positive Bethesda result (23 with positive ELISA result).
There is a reasonable correlation between the two methods
Patients with severe inherited haemophilia (n:33) were divided into two subgroups: those
with intron 22 gene inversion (n:20), the remainder with other gene defects (n:13). As
shown in Table 4.3, in our patient subgroup with intron 22 gene inversion, 40% (8120)
were positive by ELISA, exactly the same result as revealed by the Bethesda assay (40%
positive, 8120). In the subgroup without the inversion, positive results were found in 38o/o
(5/13) and 46Yo (6113) of the patients, as determined by ELISA and the Bethesda assay
respectively. Again, the two methods for detection of factor VIII antibodies showed a
similar sensitivity in both patient subgroups. This was different from the previous study
(Vianello et al., 1997), where they showed a much higher percentage (8lo/o, 13/16) of
positive results detected by ELISA in patients with the intron 22 gene inversion. Table 4.3
gives a comparison of our study and the study by Vianello et al. (1997) on the antibody
detection in patients with severe haemophilia with and without intron 22 gene inversion.
3.3 Different Føctor VIII Products to Set up the ELISA Method
A difference between our study and those of Dazzi et al. (1996) and Vianello et al. (1997)
was that we used formulated recombinant factor VIII whereas the previous work was done
using pure unformulated recombinant factor VIII, to carry out the ELISA. Therefore an
attempt was made to set up the ELISA using another source of factor VIII. Both AHF and
































FIGURE 4.3 The Correlation befween the Bethesda
Titre and the OD Value in ELISA
Assay in 23 Patients
Among 50 patient samples studied with both the Bethesda assay and
ELISA method to detect factor VIII antibodies,24 showed a positive
Bethesda titre, and 23 out of these patients, also showed a positive
ELISA result. The correlation (RÍ:0.72; P:0.0001) was showed as the





TABLE 4.3 Comparison of the Two Studies on Factor VIII Antibody
I)etection in Patients with Severe Haemophilia
Our Group (N = 33)
Patients with inversion, n:20 Patients without inversion, n: 13
ELISA +: 8/20:40% ELISA + 5ll3 :38Yo
Bethesda +: 8120:40o/o Bethesda *: 6113:46Yo
European Group (N = 33) (Vianello et al., Br J Haem 1997, 97. 807-9)
Patients with inversion, n: 16 Patients without inversion, n: 17
ELISA + 13/16:81% ELISA +: 6117 :35%o
Bethesda *: 4116 :25o/o Bethesda *: 3ll7 : l7%o
test was then performed on a number of different antibodies including monoclonal
antibody, normal plasma, and some patient samples. The results for the three different
factor VIII sources using monoclonal antibody ESH 8 are shown in Figure 4.4. The results
show that for AHF there was a weaker factor VIII concentration dependent curve compared
to use of RecombinantrM and unformulated recombinant factor VIII (Baxter). Therefore
AHF proved to be less suitable for use in this assay and study. The unformulated
recombinant factor VIII appeared to perform well and would be suitable for use in future
studies. The standard ELISA method using Baxter unformulated factor VIII has been
established, with a view to screening our patient plasma samples. This will be helpful to






















FIGURE 4.4 Three Different Factor \IIII Products to Coat
the Microtitre Plates in ELISA Method
This diagram shows the binding curves of a monoclonal anti-factor VItr
antibody (ESH 8) to three different products of factor immobilised on
microtitre plates. These three products were: plasma-derived factor VIII
tt4I{p (fúgh Purity)" from CSL, formulated recombinant factor VItr
"RecombinaterM" from Baxter, and unformulated recombinant factor VItr also
from Baxter. The factor VIII concentration used to coat the plates was 5
IU/ml, the same for all the products. Ten dilutions (from l/500 ro 11256,000)
of ESH 8 were tested.
4. Chapter Discussion
The possible alteration in the structure of the factor VIII molecule during the
manufacturing process may cause a change in its antigenicity, thus inhibitors may develop
as an immune response to it. In addition, it is suggested that the gene defect which leads to
production of an abnormal factor VIII, is also responsible for the induction of the immune
response towards a foreign factor VIII in those patients. Therefore, it is considered that the
sequences these antibodies target may involve both functional (coagulant) and non-
functional (non-coagulant) portions of the factor VIII molecule (Gilles et al.,1993; Hoyer,
1995). Thus, depending on the epitope, factor VIII antibodies may be or may be not
capable of neutralising FVIII:C activity.
Measurement of factor VIII antibodies is routinely performed by the Bethesda assay which
detects only antibodies that inhibit function. This assay has been functioning well in the
treatment and clinical evaluation of the haemophilia patients with inhibitors. However,
non-inhibitory antibodies may nevertheless theoretically affect the biological half-life of
infused factor VIII and be clinically relevant (Regnault and Stoltz, 1994; White, 1994).
Therefore a method which can detect binding to both functional and non-functional
epitopes could possibly provide useful information. For this reason, immunoassays that
are based on measurement of the binding between the antigen and antibody rather than the
measurement of physiological function have been adopted by some researchers to explore
the detection of factor VIII antibo dies (Dazzi et ø1., 1996; Scandella et al., 1998). A future
possible advantage is that some of those immunoassays (such as ELISA, or
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immunoprecipitation) could be more sensitive than the Bethesda assay for detection of
antibodies, and may eventually prove to be clinically useful'
To assess and veriff the presence of both inhibitory and non-inhibitory factor VIII
antibodies, an ELISA method using recombinant factor VIII RecombinaterM as antigen to
coat the plates was established. Twenty normal plasma samples were tested to give a
normal range for the OD readings. The result for the ELISA method compared with the
Bethesda assay on 50 haemophilia patients showed that the ELISA method has a similar
sensitivity to the Bethesda assay for the detection of factor VIII antibodies. Of the 24
samples with a positive Bethesda titre,23 showed a positive ELISA result, while none of
the 26 samples with negative Bethesda titre were positive by the ELISA method.
Furthermore, it was demonstrated that there is a weak but definite correlation (Ñ:0.72;
P:0.0001) between the optical density in the ELISA assay and the Bethesda titre, when the
26 pairs of OD readings (linear scale) were plotted against the inhibitor titres in BU/ml
(logarithmic scale).
In our study, the detection of the presence of an inhibitor by the ELISA method in patients
who have an inhibitor by the Bethesda assay may reflect binding of antibodies to functional
sites only. However, in some or all patients it may also reflect additional binding to non-
functional sites.
The results by the ELISA method were also evaluated in the 33 patients who had severe
haemophilia as a separate group. In the 20 patients who had the intron 22 inversion
mutation, eight were positive by Bethesda assay and all were also positive by ELISA. In
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the 13 patients with severe haemophilia but without the intron 22 inversion mutation, six
were positive by Bethesda assay and all but one was also positive by ELISA. Such results
conf,rrmed again the correlation between the two methods for detection of inhibitors. Our
results for inhibitor prevalence in patients with the inversion mutation (40% by both
ELISA and Bethesda methods) agree with these found in the haemophilia A website
HAMSTeRS data base, where 35-40Yo of patients with the inversion mutation had inhibitors
(Tuddenham and McVey, 1998). In our study, the similar sensitivity of the ELISA method
compared with the Bethesda assay, was different from some studies by an European group
(Dazzi et a1.,1996; Vianello et al., 1997). Their conclusion was that the ELISA method
revealed a higher prevalence of inhibitors in those patients with a negative Bethesda titre.
It is of interest that our results differ from these in previous studies (Dazzí et al., 1996;
Vianello et a1.,1997). V/e did not conf,rrm their findings that some patients had inhibitors
that were positive by ELISA but were negative by Bethesda assays. One may argue that
such difference could be ascribed to different cut-off values for "positivity" by ELISA in
the two studies. However, this is not likely to be the source of bias given the actual data.
The cut-off OD value used in our study was 0.29, which was calculated from the mean
value of the 20 normal controls plus 3 SD. Even if we used the maximum OD value from
the control group as the cut-off value (the European group used the highest value of six
normal controls), it would not change the result of "positive" or "negative" in any of our 50
patients. Nevertheless, there could be a number of possible reasons count for the
differences found in our study and the European study. They are, firstly, methodological
factors, which may be very important. The most likely factor in our study is the source of
factor VIII used to coat plates. Different factor VIII products may have different epitopes
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exposed on the microtitre plates. The factor VIII used by Dazzi et al. (1996) and Vianello
et al. (7997) was unformulated recombinant factor VIII supplied by Baxter. For our study,
we used the formulated Baxter product. Further work with the unformulated product is
necessary to determine if these products have different antigenic properties in the ELISA
method. Secondly, one has to consider whether there might be differences in the patient
population, particularly in the prevalence of the different causative mutations. However, it
is likely that our population is very similar to that examined in the European studies. The
third possibility is that there may be environmental factors that are different in the
Australian population. This could include the type of replacement therapy that the patients
received. In Australia, AHF made by CSL is used exclusively for those patients treated
with a plasma-derived product. In other countries, e.g., in Europe, other products from a
variety of manufacturing methods are used. It is likely that the factor VIII concentrates
produced by different manufacturing technique lead to the exposure of different epitopes
on the factor VIII molecule. It is well described that some products have proved to be
excessively antigenic (Rosendaal et a|.,1993; Peerlink et al.,1997; Vermylen, 1998). Two
products have been withdrawn from use after the development of inhibitor in a number of
cases who had been previously treated with other products without inhibit formation
(Rosendaal et a|.,1993; Peerlink et a|.,1997).
The sensitivity and reliability of our ELISA method still needs further confirmation, using
at least one other source of factor VIII to coat the plates. For this reason, we have very
recently optimised the ELISA for use with unformulated recombinant factor VIII to coat
the plates. Initial experiments demonstrated that unformulated recombinant factor VIII
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will be suitable for use in the ELISA method. In the future, it is planned to retest our group
of patients using the unformulated factor VIII to detect antibody binding.
It is worth mentioning that there was one case of an unexpected discrepancy between
methods, with a negative result by ELISA and the presence of inhibitors by the Bethesda
assay. The inhibitor titre was 4 BU/ml þatient "Severe 26", Table 4.1). Such a
cliscrepancy was also reported in Vianello's study (Vianello et al., 1997). This suggested
that immunoassays such as ELISA, cannot detect all types of anti-factor VIII antibodies.
This might be related to the conformational changes of the epitopes on the factor VIII
molecule during production, immobilising or testing procedures, which then become
unrecognisable to some antibodies. Another explanation may be related to the
affinitylavidity of the antigen-antibody complex reflected in the ELISA method. The
inhibitors in this case may have had a loose-binding to the immobilised factor VIII antigen
on the microtitre plate, so as to give a low OD reading which was not comparable to the
degree of inhibition of FVIII:C as detected by the Bethesda method. It will be of interest to
detect whether this patient's inhibitor is type I or type II.
5. Chapter Summary
In summary, the establishment of immunoassays such as ELISA provides an alternative
way to examine the immune response to factor VIII in haemophilia A patients, in addition
to the traditional coagulation tests
o An ELISA method using recombinant factor VIII to coat the microtitre plates has been
established to detect anti-factor VIII antibodies. The cut-off OD value 0.29 in 1/100
plasma sample dilution was used to define a positive or negative ELISA result.
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o The ELISA was run in parallel with the Bethesda assay on 50 haemophilia A patients
and showed a similar sensitivity for detection of factor VIII antibodies. There was a
correlation between the Bethesda titre and the OD found in ELISA tests. In studies
reported by others there has been a lack of correlation, with many patients who were
negative by functional assay testing as positive by ELISA.
o The discrepancy between our study and other studies may reflect methodological
differences. It is very important to repeat our study using different sources of factor
VIII to coat the plates. The discrepancy may also be caused by the differences in the




EPITOPE DETECTION ON FACTOR VIII PEPTIDE
l.Introduction
Factor VIII is a high-molecular-weight glycoprotein composed of three different types of
domains arranged in the order NH2-41-42-B-A3-CI-C2-COOH, as deduced from the
cDNA sequence (Wood et al., 1984). It circulates in the plasma as a heterodimer of a
heavy chain (Al-42-B) and a light chain (A3-CI-CZ) linked by a metal ion bridge. The
anti-factor VIII immune response is polyclonal, and antibodies are directed towards almost
any region or domain (Gilles et al.,1997)
Initial epitope mapping studies utilising characteristic thrombin cleavage fragments of
factor VIII in immunoblots noted that epitopes resided on both the heavy and light chains
(Fulcher et a1.,1985; Fulcher et a1.,1987). Approximately one-third of patients produced
inhibitors which bound to the heavy chain, one-third bound to the light chain and one-third
bound to both the heavy and light chains. Bacterial expression clones of fragments of the
factor VIII gene, either intact or with engineered deletions, were used to localise the
epitopes further down to the A2 and the C2 domains (Scandella et al., 1988; Scandella e/
al., 1989). 'When the variable recombinant fragments were tested for inhibitor antibody
reactivity on immunoblots, most inhibitor-containing plasma was strongly reactive with
epitopes mapping either to residues 379-538 of the heavy chain, residues 2178-2332 of the
light chain, or both. In addition, other less commonly reactive epitopes were localised to
the amino terminal end of the light chain within the A3 or C2 domains (Scandella et al.,
1988). Epitopes in the A1 and B domains have rarely been reported.
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As discussed in Chapter 3, the different kinetics of inactivation of factor VIII seen for
inhibitors may be a consequence of the binding-site on the molecule. Also, other features
of the inhibitor response, e.g., responder group, cross-reactivity to porcine factor VIII, high
versus low titre, may be related to the specific epitopes
To explore these concepts further I undertook development work to study epitopes on the
factor VIII molecule. Therefore the specific chapter aims were:
1) To establish a method to produce factor VIII heavy and light chain fragments, using
thrombin to cleave the molecule and immunoblotting to detect antibody binding
2) To investigate the use of a bacterial (8. Coli) expression system to produce recombinant
factor VIII fragments (in particular, domain Al), with a view to using this fragment to
screen factor VIII antibodies (including monoclonal antibody and patient antibody)
2. Methods
The generation of thrombin-cleaved factor VIII fragments followed by immunoblotting
was one of these earlier methods used to locate epitopes (Fulcher et a1.,1985; Fulcher e/
al., 1987). This approach allows binding to heavy and light chain specifically to be
determined, as well as binding to the smaller products of the activation and inactivation
steps. The method used is described in Chapter 2, section 3.3.2.
For the majority of these experiments the source of factor VIII was RecombinaterM
(Baxter), the recombinant therapeutic product which contains a number of stabilisers
including albumin at 12.5 mg/ml. Unformulated recombinant factor VIII (also from
Baxter), without albumin, was available towards the end of the project. The concentration
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of FVIII and thrombin used were similar to those previously described. The primary
monoclonal antibodies used included MAS 530 and MAS 53I at 1/100. These antibodies
had no detectable activity in a Bethesda assay and therefore BU/ml can not be given
(results not shown). ESH 8 was also studied, at dilution of 1/1000. This antibody, which
is directed against a light chainlC2 epitope, showed inhibitor activity in the Bethesda assay
(approximately 3,000 BU/ml, results determined by routine laboratory) and ELISA method
(Chapter 4). In patient studies, IgG from two patients with 7 and 43 BU/ml activity was
used, and diluted to 1/100 for the immunoblotting procedure. The secondary antibodies
(with HRP linkage for the ECL detection step) were anti-mouse IgG for the monoclonal
antibodies and anti-human IgG for use with the patient studies. During the
immunoblotting procedure the gel was cut into strips as required to allow the appropriate
incubations.
My attempt to use a bacterial expression system to produce the Al domain was
unsuccessful. Nevertheless, considerable time was spent working on each phase of the
system to produce recombinant protein. The methods used are described here, and the
problem arising at various stages are given in the Results section. The procedure followed
for expression vector cloning basically included: PCR to make the target gene, insertion of
target gene into the vector, transformation of the vector to E. Coli cells, screening the
transformed cell clones, induction of target gene expression, and protein purification.
Methods were described in Chapter 2, Section 3.3.1
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3 Results
3.1 Thrombín-Cleaved Fragments of Recombinønt Føctor VIII
RecombinaterM was incubated with thrombin in a time course study (incubation time: 0
min, 10 min, and 20 min) and then incubated with either monoclonal antibody ESH I (anti-
C2 domain of light chain) or MAS 530 (anti-heavy chain), as shown in Figure 5.1. There
were two bands shown at the size of heavy chain fragments (-50 KD, 45 KD) as detected
by MAS 530, in lanes loaded with thrombin cleavage samples (10 min flane 8] and 20 min
flane 7] incubation samples). There were no 45-50 KD bands found with the uncleaved
TFVIII sample lane (lane 9). Probing with the monoclonal antibody ESH 8 did not show
any binding results. Cross reaction between the antibodies and albumin (at 6l KD) caused
signifi cant interference.
In the next experiment monoclonal antibodies MAS 530 (anti-heavy chain) and MAS 531
(anti-light chain) were used. As shown in Figure 5.2, two small fragments (-50 KD)
similar to those seen in the previous experiment, were demonstrated by MAS 530 to bind
to the heavy chain product. This again occurred only in the thrombin-cleaved TFVIII
sample lanes (lanes 2 and 5). Anti-light chain antibody MAS 531 did not show any
specific binding to factor VIII fragments
Based on the positive western blot result of MAS 530 binding to thrombin cleaved TFVIII
fragments, we further investigated this detection method with some of the samples from
our inhibitor patients. Figure 5.3 shows the results obtained from IgG concentrates of two
of our patients with severe inherited haemophilia (Case 3 and Case 5 in Chapter 3). As
before, MAS 530 was used for a positive control (binding with two small fragments as
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FIGURE 5.1 Time Course of Thrombin Cleavage of Recombinant
X'actor VIII Detected by Western Blot, Using Two
Monoclonal Antibodies
Column M: molecular weight markers (KD).
Column B: blank (loading buffer only).
Column 2-5: detection with monoclonal antibody ESH 8.
Column 7-10: detection with monoclonal antibody MAS 530.
Column 2 & 7: thrombin incubated with TFVIII for 20 min.
Column 3 & 8: thrombin incubated with TFVIII for 10 min.
Column 4 &,9: thrombin incubated with TFVIII for zero min.
Column 5 & 10: albumin control, for identification of this contaminant by its molecular
weight.
The arrows on the right hand side indicate the expected products after heavy chain











FIGURE 5.2 'Western Blot for Thrombin-Cleaved Recombinant Factor
VIII, Using Both Anti-heavy Chain (MAS 530) and Anti-
Light Chain (MAS 531) Monoclonal Antibodies
Column M: molecular weight markers (KD).
Column B: blank (loading buffer only).
Columns 2-6: detection with anti-heavy chain monoclonal antibody MAS 530.
Columns 8-10: detection with anti-light chain monoclonal antibody MAS 531.
Columns 2 &,3,5 &,6, and 8 &,9: eachpair loaded with thrombin-cleaved TFVIII (15 min
incubation) and zero control (TFVIII plus HrO instead of thrombin) respectively. Dose
effect was studied with MAS 530 detection by reducing to half the amount loaded in lane
paires 2 &,3.
Column 4 &. I0 albumin control, for identification of this contamination by its molecular
weight.
The arrows on the right hand side indicate the expected products after heavy chain
breakdown (in lanes 2 8. 5), which can be detected by MAS 530 as described before.
However, there was no binding for MAS 531 (lanes 8 & 9) to any potential factor VIII















FIGURE 5.3 Western Blot for Thrombin-Cleaved Recombinant Factor
VIII, Using Monoclonal Antibody (MAS 530) and
Human IgG Concentrates
Column M: molecular weight markers (KD).
Column 2, 3 &.4: loaded with zero control TFVIII (TFVIII plus HrO instead of thrombin),
thrombin-cleaved TFVIII (15 min incubation), and albumin control respectively. Probed
with monoclonal antibody MAS 530.
Columns 5,6 &,7,and 8,9 &10: the samerFVIII orderas inlanes 2,3 &,4, butprobed
with IgG concentrates from two patients with inhibitors (Case 3 Hu and Case 5 Lo).
The arrows on the right hand side indicate the expected bindings of the heavy chain
fragments after cleavage (lane 3) to MAS 530, as shown before. However, there were only
background signals in lanes 5-7 probed by IgG from Case 3, and a totally blank gel in lanes




shown in lane 3, which was a thrombin-cleaved TFVIII sample lane). However, no binding
could be demonstrated for either patients'IgG: one showed a high background signal, while
the other gave no signal.
Towards the end of this study, we were able to use unformulated TFVIII (a gift generously
provided by Baxter) to set up western blot analysis of thrombin-activated TVIII. Therefore,
the interference by albumin in formulated TFVIII was avoided. The result is shown in
Figrne 5.4. There was binding to bands similar to those in previous studies detected by
MAS 530 in lanes 3 and 5, which were loaded with different amounts of thrombin-cleaved
unformulated TFVIII (15 min incubation). Again, monoclonal ESH I did not show any
evidence of binding
3.2 Bscterial Vector Expression of Factor VIII Fragment Al
The following shows results of attempts to produce recombinant A1 fragment. Attempts to
produce heavy chain, AllA2, and A2 fragments were also performed during the research
period of this project, with none of them, however, achieving any successful result. This
work was performed in conjunction with a current research project carried out in the
Molecular Pathology Division at IMVS. The method and results following show parts of
the work I undertook to produce the A1 domain. The principle used to produce the Al
domain can be applied to other segments of factor VIII
Briefly, the main work with recombinant DNA technology to produce protein fragments
comprised: a) PCR to make a target gene. b) Insertion, transformation, and screening for
the specific cell colonies that contained the inserted vector and target gene. c) induction
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F'IGURE 5.4 watern Blot for Thrombin-cleaved unformulated
Recombinant Factor VIII (Baxter), Using
Monoclonal Antibodies MAS 530 and ESH I
Column M: molecular weight markers (KD)'
Column B: blank'
Column Z &, 3, 4 & 5: loaded with zero control TFVIII (unformulated TFVIII plus HrO
instead of thrombin), thrombin-cleaved unformulated TFVIII (15 min incubation), in the
two lanes respectively. The samples loaded in lanes 2 &, 3 were double the amount loaded
in lanes 4 &,5. All probed by monoclonal antibody MAS 530.
Columns 7 &, 8, 9 &, l0: duplicates of the lanes 2 &, 3, 4 & 5, but probed by monoclonal
antibody ESH 8.
The arrows on the right hand side indicate the expected bindings of the heavy chain
fragments of the unformulated factor vIII after cleavage (lane 3 and 5) to MAS 530, as the
same seen before. Again nothing came up with the monoclonal antibody ESH 8' With this
product there is no interfering band of albumin'







and purification of the protein. Figure 5.5 shows the evidence of a successful PCR result
for A1 gene. Gel electrophoresis showed a clear band of the right size for the A1 gene
(-1.3 kb), while there was no band in the non-cDNA control lane.
After purification of the PCR products, digested by BamH I restriction enzymez ligation
was set up to insert the A1 gene into the vector pGEX-2TK. Then the vector was
introduced into an E. Coli competent cell, DH5cr, and allowed to grow on LB-Amp agar
plates af 37"C. By destroying the cell structure and running the DNA components on the
gel, it was possible to select those colonies with a successfully inserted vector gene. V/ith
these clones, in addition to a large band which indicated the cell gene itself, there was
another band of the right size for the vector gene (-4.8 kb) plus the A1 gene. As shown by
Figure 5.6, among quite a few randomly selected colonies, it appeared only the No. 21
colony demonstrated the inserted vector, with the affow indicating the extra DNA band of
the right size.
Colony 2l (and also 14) were selected and then put into a large culture for protein
expression. Figure 5.7 shows the results of induction using IPTG. "GEX" was the vector
alone, used as a control, in the induction procedure. After induction, if the cell would
express A1 domain successfully, there would be an extra band corresponding to the size
which is indicated by the affow with the short dashed line on Figure 5.7. There was no
extra band in lanes of the I,2 or 3 hour time points of the induction process as compared
with that in the zero point sample lane, or compared to the GEX control, at this molecular
weight. There was an extra band for the GEX control, at the approximate molecular weight
of the vector (solid arrow), expressed after I hour induction.
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FIGURE 5.5 PCR Products for the Al Gene
Column M: molecular weight markers for DNA (kb), does not show up well on this
photograph.
Columns 3,4 8.5: with PCR products at the expected molecular weight (-1.3 kb for the
A1 gene), as indicated by the anow.
Column C: negative control without cDNA put in prior to the PCR reaction, showing no
PCR products.
M 2 3 4 5 C
A1
FIGURE 5.6 Colony Screening for the Insertion of A1 Gene into the
Vector
Column M: molecular weight markers for DNA (kb), does not show up well on this
photograph.
Colony 21, shows a band indicated by the left hand arrow, which suggests incorporation of
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FIGURE 5.7 IPTG Induced Protein Expression by Colony 21
Coomassie Blue to stain the gel.
Column M: molecular weight markers for protein (KD).
Samples were taken at different time points after adding the IPTG. GEX indicates vector
alone, and A1 indicates the samples taken from the transformed culture.
The dashed arrow indicates the molecular weight of the expected Al peptide.
The solid arrow shows the expected molecular weight of the vector alone.
A1 GEX












Thrombin-cleaved recombinant factor VIII fragments, namely, the heavy chain and its
activation/inactivation products demonstrated binding with monoclonal anti-heavy chain
antibody MAS 530. This was an initial experiment to show that epitopes could be
detected. The method was then used in our patients to detect binding of patient inhibitors.
It is important to mention that immunoblotting may cause lots of antigenic determinants
due to denaturation, and it may therefore not be possible to detect the binding of antibodies
to those epitopes (Hoyer, I99I; Hoyer and Scandella,1994; Scandella, 1996). In addition
to immunoblotting, other antibody binding assays such as immunoprecipitation should also
be valuable in epitope determination. Also, identification of the clinical relevance of
specific epitopes requires an antibody neutralisation assay, in which the same soluble
factor VIII peptide as found with binding is tested for its ability to neutralise the inhibitory
function of the antibody to FVIII:C (Scandella et al,1995 b).
The failure in expression of factor VIII fragments in E. Coli cells illustrates the difficulty
of this method. More work needs to be done in order to optimise the molecular biological
conditions which are required for successfully producing a fragment. Theoretically, once
set up, this method can be easily adapted to produce a variety of factor VIII fragments in a
range of sizes.
However, we showed evidence of insertion of the vector gene (with Al gene) into the cell,
as the colony screening shown in Figure 5.6. Therefore, we consider the reasons that the
A1 protein was not expressed might be: 1) the product is toxic to the cell. 2) the induction
l0r
conditions need to be optimised. 3) the cell line is not reliable, or the cell line is not
suitable for the production of A1 domain. In addition, there might had been some A1
protein produced, but it was very unstable or insoluble, so that it was not detected. We
have become aware that other research groups working on the factor VIII protein are
finding that insect cell lines are superior to E. Coli for the production of factor VIII and
fragments of factor VIII. Since my project, the use of insect cell lines has been introduced
in our laboratory.
In this study thrombin cleaved fragments of recombinant factor VIII protein were
generated with the aim of determining heavy and light chain specificity of inhibitors.
Whilst successful with a monoclonal antibody model the approach was unsuccessful for the
study of IgG purified from patient plasma. This is likely due to insufficient sensitivity of
the system f'or the relatively low levels of anti-factor VIII antibody tested (-7-40 BU/ml
from patient IgG concentrates). Further directions for this work could include the use of a
more sensitive detection system in the immunoblotting method (e.9., streptavidin-biotin or
It25 labelled secondary anti-human antibody). Also, the production of recombinant factor
VIII fragments would allow more precise localisation of epitopes
The mechanisms by which factor VIII inhibitors inactivate FVIII:C are variable. At least
one mechanism, which is relevant to inhibitors with light chain specificity (C2 domain), is
interference with normal factor Vlll-phospholipid interactions (Arai et a1.,1989; Fulcher,
l99l; Saenko and Scandella,1995), and maybe factor VIII-vWF binding as well (Gilles e/
al., 1999; Saenko et al., 1994). It has also been suggested that inhibitor antibodies may
interfere with thrombin cleavage of the factor VIII molecule (Lazarchick et a|.,1986). Yet
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another more speculative mechanism is by blocking of its interaction with factor X and
factor IX (Fulcher,I99l; Hoyer 1991). Recent study has confirmed that some factor VIII
inhibitors with anti-A3-C1 IgG act by prevention of the FVIIIa/FIXa association (Zhong et
a1.,1998). In addition, a previously unknown mechanism by which inhibitors may act on
FVIII:C was demonstrated to be by causing the proteolysis of factor VIII by inhibitor IgG
at the major sites between the A1 and A2 domains (R372-S373); N-terminus of the A3
domain (Yl689-D1681); and 81794-D1795 in the A3 domain (Lacroix-Desm¿ves et al.,
1999). There is as yet no evidence for a relationship between definite inhibitor epitopes
and the kinetics of the binding to and inactivation of factor VIII.
Epitope mapping is of therapeutic interest for the future. Mutant factor VIII molecules
which contain amino acid substitutions in epitope regions could be synthesised by
recombinant DNA methods. The molecules could be designed to be non-reactive with
inhibitors. If such antibody-resistant molecules are fully active and have a normal
circulating half-life, they could be used to treat the patients effectively.
6. Chapter Summary
Epitope detection on the factor VIII peptide is no doubt a critical task for our better
knowledge of the immunochemistry of the anti-factor VIII antibodies. Although the
methodology remains a challenge, using recombinant DNA technology to produce factor
VIII peptides with any desired size still seems to be a reasonable way to carry out a
thorough study of epitope determination. Future direction may also include attempts to
explain the inactivation mechanisms. Information about the immunobiology of factor VIII
inhibitors, mainly the epitope specif,rcity, may help us to understand factor VIII inhibitor
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formation in the same rway that investigators are beginning to understand the pathogenesis




Human antibodies that inactivate FVIII:C are detected in approximately 25% of
multitransfused patients with haemophilia A. These inhibitory antibodies (inhibitors) arise
as an immune response to infused factor VIIL Less commonly, factor VIII inhibitors also
develop as autoantibodies in individuals with previously normal haemostasis. Patients
with genotypes (such as inversion, large deletion, and stop codon mutation) associated with
the most severe clinical phenotypes pose a greater risk of developing factor VIII inhibitors
(Reding et al., 1999). Factor VIII replacement therapy in these cases is less effective or
ineffective and clinical management may be exceptionally difficult.
Factor VIII inhibitors have been classified according to their in vitro kinetic behaviour.
Generally, type I inhibitors, which are more commonly seen in patients with severe
inherited haemophilia, have second-order kinetics and completely inhibit exogenous
FVIII:C. Type II inhibitors follow more complex kinetics, and do not completely inhibit
FVIII:C (Biggs et a1.,1972 a and b; Gawryl and Hoyer,1982). However, previous studies
have all used different methods and criteria to classifr inhibitor type. There has been no
evaluation of the effectiveness of these different methods to classiff inhibitors in a single
group of patients
Biggs et al. (1972 a and b) described linear inactivation on a time course graph as typical
for type I kinetics, but their graphical representations are not consistent with this statement.
In particular, as well as graphs of type I kinetics that are linear, they also showed graphs
that are curvilinear. These latter graphs show a steep decline followed by a continuous
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gradual decline. This is in fact not different from their graph for a typical type II pattern.
The descriptions by other authors (Allain and Frommel, 1974; Green et al., 1997) are also
inconsistent and contradictory. The only approach which appears straightforward is that
described by Gawryl and Hoyer (1982). In their approach, they measured the effect of
varying the concentration of inhibitor rather than a time course. V/e therefore studied
inhibitors from a group of patients and examined the effects of incubation time and effect
of antibody concentration on the kinetics of inactivation of factor VIIL
The results of the time course study showed that inhibitors from eight out of the nine
patients demonstrated a similar pattern of inactivation of FVIII:C, which was characterised
by a rapid initial decrease of residual FVIII:C (%) followed by a gradual continuous
decline. In addition, mathematical analysis did not show any features that would allow
separation into two groups. Therefore, by this approach all of these eight cases appear the
same, and we cannot distinguish whether they have type I or type II kinetics. Only one
case (Case 11) showed a slow linear inactivation on the time course graph, which by Biggs'
criteria would be type I. However, this case later on was defined to have a type II inhibitor
In our studies of the in vitro kinetics of faotor VIII inhibitors, by the study of the effect of
antibody concentration, we were able to divide the 11 patients with haemophilia A into two
groups. The classif,rcation results were obtained by both visual observation of the antibody
concentration graph (using patient plasma or purified and concentrated IgG) and
mathematical analysis of the data. These groups corresponded to the two groups described
by Gawryl and Hoyer (1982). Five patients with severe inherited haemophilia were all
found to have type I inhibitors. Three mild inherited cases were studied, and two with type
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I and one with type II kinetics were found. Three acquired cases were studied and one
showed type I kinetics and two showed type II pattern. Therefore, a patient's clinical group
does not always determine the kinetic type of their inhibitors. While it may be more
coÍìmon for patients with acquired haemophilia to have type II inhibitors, some patients
may have inhibitors with type I characteristics which completely neutralise all factor VIII.
Also, in patients with inherited mild haemophilia, either type I or type II inhibitors may be
seen. Expanding this study to classiff more patients would give a better estimate of the
prevalence of the two types of inhibitor in these clinical groups
Hence studying the effect of antibody concentration provides a straightforward approach to
the classification of inhibitors. By contrast, study of the time course was in our patients
relatively non-productive. Nevertheless, we also studied the time course by an alternative
approach in four patients. After incubating factor VIII with inhibitor for four hours, further
factor VIII is added to the incubation mixture. In Biggs' studies a type II inhibitor will
inhibit this additional factor VIII whereas a type I inhibitor will not. Biggs interpreted this
as evidence for weaker binding of type II inhibitors. 'We were able to demonstrate this
phenomenon in patients who had been classified as type II by study of antibody dilution,
but not in those who were type I. This is therefore consistent with Biggs' finding.
However, this approach did not provide a straightforward way to distinguish the inhibitors.
This is because the interpretation is dependent on obtaining a critical ratio of factor VIII to
inhibitor in the incubation mixture.
Our study has for the first time, used a number of previously described methods (namely,
examining both the time course and the effect of antibody concentration) in a relatively
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large group of patients, in order to assess these two methods for classification of their
inhibitor type. Our conclusion is that study of the time course does not provide a means of
readily classifying these patients. Therefore, for a standard approach to the classification
of factor VIII inhibitors based on in vitro kinetics, we recommend studying the effect of
antibody concentration. A plasma dilution study is suitable for high-titre inhibitors (>10
BU/ml). A type I inhibitor is characterised by a steep slope and complete (>98%)
inactivation of FVIII:C at higher antibody concentrations, while a type II inhibitor gives a
plateau and incomplete inactivation even at high antibody concentrations. Purified and
concentrated IgG is helpful for the study of antibodies which are not present at high
enough levels in plasma. Mathematical analysis would strengthen confidence in the
interpretation made by visual observation of the curves.
In our studies we have examined only I I patients. It would be of interest to expand this
work to include the application of this approach to a larger number of patients, covering as
many variables as possible, i.e., patients with different clinical severity, different gene
mutations, different replacement therapy (e.g., children receiving recombinant factor VIII,
and adult patients receiving AHF), and patients from a wider range of sources, e.g., patients
from different regions, and different racial groups. It would be important to study both the
time course and the effect of varying antibody concentration. Although the study of the
time course was not fruitful in our study, examining a large number of patients may
disclose the presence of different types of time course. In particular, it is of interest to
determine whether or not there is a small group with a linear time course such as that
described by Biggs and found in only one of our patients.
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There are two possible hypotheses to explain the complex kinetics of type II inhibitors.
One is that type II inhibitors have relatively low aff,rnity binding to the factor VIItr
molecule (Allain and Frommel,l974; Gilles et a|.,1997; Hoyer and Gawryl,1984; Kasper,
1984). It is therefore possible for them to dissociate from the original factor VIII
molecules which remain inactivated, and bind to additional factor VIII molecules which
also become inactivated. This explains the effect on an extra amount of factor VIII added
during the time course experiments (Figure 3.9). Another hypothesis for the type II
kinetics is that these inhibitors only partially inhibit FVIII:C. This could, occur for
instance, if they blocked only part of an important functional site. Such a hypothesis
explains the plateau (incomplete inactivation) on the antibody concentration curve even
when inhibitor is present at high concentration. However, this does not explain their
ability to inactivate an extra source of factor VIII added after equilibrium is apparently
reached.
Inhibitory antibodies bind to one or more of the factor VIII epitopes which are essential for
procoagulant activity. Epitopes recognised by factor VIII inhibitors have been mapped to
three main clusters located in the A2, A3 and C2 domains on factor VIII molecule (Lollar,
1999). The majority of factor VIII inhibitors are directed against one of the following
areas:
1) the carboxyl end of the C2 domain, which contains phospholipid and vV/F binding sites;
2) the amino end of the A2 domain, which is responsible for the interaction with factor Xa;
3) the amino end of the A3 domain, which contains a factor IX binding site (Reding et al.,
1999). It is possible that the complete inactivation of FVIII:C by type I inhibitors may be
caused by the complete blockage of any of those important functional regions. For type II
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inhibitors, the incomplete inactivation of FVIII:C may be due to partial blockage of those
reglons.
Inhibitor neutralisation studies indicate that the effects of anti-A2, anti-43, and anti-C2
antibodies on the Bethesda titre are additive (Prescott et al., 1997). Thus, inhibitors to a
given domain appear to act independently of inhibitors to other domains. Haemophilia
inhibitors and autoantibodies have the same broad domain specificity, which is somewhat
surprising given the different immunologic settings in which they arise (Lollar, 1999).
There is evidence that a proportion of anti-factor VIII antibodies do not inhibit the
procoagulant function of the molecule (Gilles et a1.,1993). This conclusion was based on
an apparent lack of correlation between inhibition of function as shown by a chromogenic
bioassay method, and amount of antibody bound to factor VIII. These antibodies have
been referred to as non-inhibitory antibodies. Such antibodies may act against non-
functional epitopes in a patient in whom there is no inhibitor against a functional epitope.
It has been suggested that they may play a role in increasing the clearance of factor VIII
from the circulation (Kessler, l99l; Nilsson et a1.,1990). This could be by increasing the
uptake of factor Vlll-immunoglobulin complexes by phagocytic cells of the reticulo-
endothelial system (Gilles et a|.,1997). The ELISA method is one immunoassay approach
that has been developed, aiming to detect both the inhibitory and non-inhibitory anti-factor
VIII antibodies (Dazzi et a1.,1996).
As part of this study an ELISA method to detect factor VIII inhibitors was established.
One way to obtain evidence for non-inhibitory antibodies is to study patients with
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haemophilia A who are negative for inhibitors by the Bethesda assay. Should these
patients be positive by ELISA, this would suggest that there is antibody binding to epitopes
that are not important for function. Our results by ELISA showed a similar sensitivity
between the ELISA method and the Bethesda assay for detection of factor VIII antibodies
in 50 of our patients with haemophilia A. Twentythree out of the 24haemophilia patients
with a positive Bethesda titre showed a positive ELISA result, while none of the 26
patients with a negative Bethesda titre was found to have a positive result by ELISA. In
addition, there was a definite correlation between the OD value of the ELISA method and
the Bethesda titre in these 50 patients.
In contrast to two previous published reports (Dazzí et al., 1996; Vianello et al., 1997), we
did not detect inhibitors by ELISA in any patients who did not have an inhibitor as
detected by the Bethesda method. Thus, in the patient group studied here, non-inhibitory
factor VIII antibodies are not a consequence of treatment with factor VIII replacement
therapy. Therefore, non-inhibitory factor VIII antibodies may be rarer in this Australian
patient group than in European studies. One possible reason might be because haemophilia
patients in Australia are treated with plasma-derived AHF exclusively from one
manufacturer (CSL). This may have an effect on the antigenicity of the factor VIII
molecule by inducing an inhibitor with a different epitope specificity to that in the
European patients where factor VIII concentrate from several manufacturers is used.
Another reason may be the different sources of factor VIII used to coat the microtitre plates
in different studies, which may lead to the exposure of different epitopes on the factor VIII
molecule.
lll
In our group of patients studied by ELISA, a reasonable number (n:20) of patients have
the inversion mutation. Intron 22 gene inversion is the most common mutation in inherited
haemophilia A with a severe phenotype. It was of interest whether this particular mutation
would lead to findings different to those found in a group of severe patients with other gene
defects. Our study showed that both ELISA and the Bethesda assay gave a similar
proportion of positive results in severe patients with (40% and 40o/o, respectively) and
without (38% and 46Yo) the inversion. The prevalence (40Yo) of inhibitors by Bethesda
assay in our severe patient group with intron 22 inversion is similar to that in other studies
(34.4% in the study by Becker et al., 1996 and 35-40% in the study by Tuddenham and
McVey, 1993). There were differences between the prevalence of inhibitors in our study
compared with the European study (Vianello et a1.,1997). In their study, 81% of patients
with severe inherited haemophilia with intron 22 gene inversion, were found to have
positive ELISA results, while only 25%o of them had detectable inhibitor by the Bethesda
assay.
A future prospective survey on a larger group of randomly selected patients may better
evaluate the applicability of the ELISA method. It will also be useful to carry out the
ELISA tests using different factor VIII source to coat the plates. Currently we do not know
the clinical importance of a positive ELISA result in a patient with a negative Bethesda
titre. It will only be important if binding of the antibody to the factor VIII molecule leads
to an increase in clearance and therefore a reduction in survival time.
The epitopes which characterise individual inhibitors may be numerous, as the human
immune response towards factor VIII is highly heterogeneous (Hoyer, l99l). It was
t12
suggested that type I inhibitors may interact with different epitopes as compared to type II
inhibitors (Biggs et al., 1972 a and b; Gawryl and Hoyer, 1982). Patients with type I
inhibitors have both arfti-A2 and anti-C2 antibodies, possibly in addition to some other
epitopes on the light chain, such as in the A3 domain (Prescott et al., 1997). On the
contrary, acquired haemophilia patients with type II inhibitors tend to have a simpler
antibody repertoire, with their antibodies more likely to be specific for a single domain (A2
or C2), but not both (Prescott et al.,1997). It is important to study larger group of patients
to correlate epitopes and kinetics.
Methods used to identify antibody binding sites (epitopes) include competition with
monoclonal antibodies of known specificity, use of cDNA-derived (recombinant) factor
VIII fragments, hybrids of human and porcine factor VIII, and synthetic peptides. All but
the first of these methods make use of the factor VIII protein or fragments thereot but do
not account for the fact that factor VIII antigenicity could be altered by conformational
changes, which are known to occur upon factor VIII interaction with vWF, or as the result
of proteolytic cleavage by thrombin (Gilles et a|.,1999)
In this study thrombin-cleaved fragments of recombinant factor VIII protein were
generated with the aim of determining heavy and light chain specif,rcity of inhibitors.
Whilst successful with a monoclonal antibody model the approach was unsuccessful for the
study of IgG purified from patient plasma. This is likely due to insufhcient sensitivity of
the system for the relatively low levels of anti-factor VIII antibody tested (-7-40 BU/ml
from patient IgG concentrates). Further directions for this work could include the use of a
more sensitive detection system in the immunoblotting method (e.9., streptavidin-biotin or
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It2t labelled secondary anti-human antibody). Also, the production of recombinant factor
VIII fragments would allow more precise localisation of epitopes'
In further studies it would be of great interest to investigate the possible relationship
between the gene defect, epitope specificity, and the clinical and kinetic behaviour of the
factor VIII inhibitors. Results of such studies may give additional information about the
mechanisms of antibody formation and their inactivation of FVIII:C, which may lead not
only to more informed and effective therapeutic approaches for haemophilia patients with
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